

# CITATION REPORT

List of articles citing

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report

DOI: 10.1016/j.bbmt.2014.12.001

Biology of Blood and Marrow Transplantation, 2015, 21, 389-401.e1.

**Source:** <https://exaly.com/paper-pdf/62765836/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1597	Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. <b>2015</b> , 100, 1228-36		16
1596	Sexual health in hematopoietic stem cell transplant recipients. <b>2015</b> , 121, 4124-31		37
1595	Chronic cutaneous lichenoid graft-versus-host disease at the area of herpes zoster infection and at a vaccination site. <b>2015</b> , 173, 1050-3		2
1594	CIDP-like neuropathies in graft versus host disease. <b>2015</b> , 20, 1-6		9
1593	Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. <b>2015</b> , 29, 1133-9		15
1592	Value of Screening Spirometry for Early Diagnosis of Bronchiolitis Obliterans Syndrome in Children After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2015</b> , 37, e462-7		8
1591	Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease. <b>2015</b> , 2015, 692175		
1590	[Ocular graft-versus-host disease]. <b>2015</b> , 112, 1027-38; quiz 1039-40		1
1589	2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 387-8	4.7	38
1588	NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 589-603	4.7	165
1587	Bronchiolite oblitérante et pneumopathies interstitielles après allogreffe de cellules souches hématopoïétiques. <b>2015</b> , 7, 95-97		
1586	Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. <b>2015</b> , 101, 438-51		17
1585	State-of-the-art acute and chronic GVHD treatment. <b>2015</b> , 101, 452-66		47
1584	Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life. <b>2015</b> , 51, 944-9		20
1583	Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. <b>2015</b> , 116, 287-93		6
1582	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1343-59	4.7	69
1581	Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. <b>2015</b> , 4, 113-126		12

1580	[Clinical Signs of Ocular Graft-versus-Host Disease]. <b>2015</b> , 232, 647-51	2
1579	The lung function score and its components as predictors of overall survival and chronic graft-vs-host disease after allogeneic stem cell transplantation. <b>2016</b> , 57, 16-28	8
1578	Adiponectin and resistin in acute and chronic graft-vs-host disease patients undergoing allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 57, 255-65	
1577	Chronic graft-vs-host disease in 2016: a major challenge and an opportunity. <b>2016</b> , 57, 1-3	2
1576	Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. <b>2016</b> , 57, 247-54	8
1575	Graft-versus-host disease management. <b>2016</b> , 117, 388-96	4
1574	Biology of chronic graft--host disease: Immune mechanisms and progress in biomarker discovery. <b>2016</b> , 6, 608-619	18
1573	Biomarkers in Ocular Chronic Graft Versus Host Disease: Tear Cytokine- and Chemokine-Based Predictive Model. <b>2016</b> , 57, 746-58	58
1572	Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?. <b>2016</b> , 57, 239-46	2
1571	Management of oral Graft versus Host Disease with topical agents: A systematic review. <b>2016</b> , 21, e72-81	7
1570	In Vivo Confocal Microscopy in Dry Eye Disease Associated With Chronic Graft-Versus-Host Disease. <b>2016</b> , 57, 4686-91	34
1569	Successful treatment with hydrogen rich water in a case of chronic graft-versus-host-disease. <b>2016</b> , 6, 177-179	2
1568	Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters. <b>2016</b> , 57, 266-75	4
1567	High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. <b>2016</b> , 57, 229-38	14
1566	Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation. <b>2016</b> , 62 Suppl 1, 44-50	15
1565	Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation. <b>2016</b> , 16, 2342-51	20
1564	Diagnostic phrasing is independently correlated with the decision to treat for graft-versus-host disease: retrospective review of colon biopsies with rare apoptosis. <b>2016</b> , 69, 802-811	30
1563	Dry Eye Disease Is Already Present in Hematological Patients Before Hematopoietic Stem Cell Transplantation. <b>2016</b> , 35, 638-43	22

1562	Acute myofascitis as a manifestation of chronic graft-versus-host disease. <b>2016</b> , 53, 327-9			1
1561	Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients. <b>2016</b> , 4, 667-671			3
1560	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <b>2016</b> , 128, 2450-2456			24
1559	Atorvastatin enhances endothelial cell function in posttransplant poor graft function. <b>2016</b> , 128, 2988-2999			52
1558	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <b>2016</b> , 128, 2350-2358			33
1557	Development, preliminary usability and accuracy testing of the EBMT 'eGVHD App' to support GvHD assessment according to NIH criteria-a proof of concept. <b>2016</b> , 51, 1062-5			12
1556	Evaluation of EPI-X4 as a urinary peptide biomarker for diagnosis and prognosis of late acute GvHD. <b>2016</b> , 51, 1137-9			7
1555	Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 752-758	4-7		13
1554	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1696-1701	4-7		44
1553	Case-Based Inpatient Pediatric Dermatology. <b>2016</b> ,			0
1552	More immune dysregulation: Sarcoidosis and chronic graft-versus-host disease after allogeneic stem cell transplant. <b>2016</b> , 2, 138-40			5
1551	Early Detection is Key: Is Handheld Spirometry the Answer?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 780-1	4-7		2
1550	Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD. <b>2016</b> , 95, 493-9			8
1549	What do we need to know about allogeneic hematopoietic stem cell transplant survivors?. <b>2016</b> , 51, 1025-31			15
1548	Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 925-31	4-7		22
1547	Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1416-1423	4-7		56
1546	Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1517-1524	4-7		9
1545	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <b>2016</b> , 127, 1502-8			119

1544	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 2084-2091	4-7	8
1543	Manejo de la enfermedad injerto contra huésped cutáneo crónico tipo esclerótico con fototerapia UVA asociado a psoraleno tónico en paciente pediátrico: reporte de un caso. <b>2016</b> , 31, 613-615		
1542	Management of Graft-Versus-Host Disease. <b>2016</b> , 1, 419-433		
1541	Pathology of Hematopoietic Cell Transplantation. <b>2016</b> , 292-332		3
1540	Chronic Graft-versus-Host Disease [Clinical Manifestations and Therapy. <b>2016</b> , 1020-1039		1
1539	Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1781-1791	4-7	44
1538	Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1867-1873	4-7	45
1537	Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. <b>2016</b> , 51, 1561-1564		28
1536	Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. <b>2016</b> , 13, 1932-1939		44
1535	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. <b>2016</b> , 128, 1528-31		34
1534	Pathology of Transplantation. <b>2016</b> ,		1
1533	Photo-induced graft-versus-host disease. <b>2016</b> , 32, 291-295		2
1532	Hematopoietic Stem Cell Transplantation. <b>2016</b> , 401-449		5
1531	Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. <b>2016</b> , 7, 15		153
1530	Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for Reducing Chronic Graft-Versus-Host Disease After Haploidentical Transplantation: Just Another Labor-Intensive Strategy, or Showing the Way?. <b>2016</b> , 34, 2812-3		3
1529	Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update. <b>2016</b> , 9, 72		18
1528	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. <b>2016</b> , 101, e312-5		6
1527	High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD. <b>2016</b> , 51, 1513-1517		10

1526	Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. <b>2016</b> , 51, 1350-1353		13
1525	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 825-33	4-7	9
1524	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 449-55	4-7	71
1523	Differentiating Skin Rash After Stem Cell Transplantation: Graft Versus Host Disease, Cutaneous Reactions to Drugs and Viral Exanthema. <b>2016</b> , 5, 12-17		2
1522	Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant. <b>2016</b> , 51, 283-5		6
1521	Bronchiolitis Obliterans: Pleading for a Pragmatic Approach. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 591-593	4-7	3
1520	Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. <b>2016</b> , 18, 172-85		35
1519	Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis. <b>2016</b> , 142, 1307-14		3
1518	Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 1860, 1615-22		3
1517	Diagnosis and management of bronchiolitis obliterans syndrome following lung or hematopoietic cell transplantation. <b>2016</b> , 10, 599-602		7
1516	Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 879-83	4-7	15
1515	Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. <b>2016</b> , 51, 728-31		17
1514	Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 710-716	4-7	104
1513	Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 51, 89-95		27
1512	Modern approaches to HLA-haploidentical blood or marrow transplantation. <b>2016</b> , 13, 10-24		169
1511	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 54-60	4-7	8
1510	Scleromatous Changes in an Abdominal Wall Graft: Graft-Versus-Graft Disease, or Chronic Graft Rejection?. <b>2017</b> , 39, 53-55		
1509	Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. <b>2017</b> , 96, 605-615		5

1508	Use of fresh frozen plasma: from the 2012 French guidelines to recent advances. <b>2017</b> , 56, 20-25	7
1507	Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. <b>2017</b> , 13, 553-569	13
1506	Clinical management of genital chronic GvHD. <b>2017</b> , 52, 803-810	26
1505	CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study. <b>2017</b> , 19, 531-542	42
1504	Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide. <b>2017</b> , 18, 235-242	16
1503	Diagnosis, Staging, and Treatment of Chronic Graft-Versus-Host Disease. <b>2017</b> , 125-138	
1502	Clinical Presentation of Mucosal Acute and Chronic Graft-Versus-Host Disease. <b>2017</b> , 29-42	
1501	Grading and Treatment of Acute Graft-Versus-Host Disease. <b>2017</b> , 57-68	
1500	Clinical Presentation of Nonsclerotic Epidermal Chronic Graft-Versus-Host Disease and Hair and Nail Changes. <b>2017</b> , 69-91	1
1499	Pediatric Graft-Versus-Host Disease. <b>2017</b> , 105-123	2
1498	Extracorporeal photopheresis for bronchiolitis obliterans syndrome after allogeneic stem cell transplant: An emerging therapeutic approach?. <b>2017</b> , 56, 17-19	7
1497	Elevated Neutrophil Elastase in Tears of Ocular Graft-Versus-Host Disease Patients. <b>2017</b> , 176, 46-52	30
1496	A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD. <b>2017</b> , 52, 745-752	12
1495	Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. <b>2017</b> , 52, 878-882	17
1494	Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. <b>2017</b> , 129, 2471-2478	156
1493	Pulmonary Function and Pretransplant Evaluation of the Hematopoietic Cell Transplant Candidate. <b>2017</b> , 38, 307-316	6
1492	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. <b>2017</b> , 57, 60-64	22
1491	Multiple and Recurrent Squamous Cell Carcinoma of the Oral Cavity After Graft-Versus-Host Disease. <b>2017</b> , 75, 1899-1905	6

1490	Late effects of blood and marrow transplantation. <b>2017</b> , 102, 614-625		90
1489	Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2017</b> , 38, 249-262		27
1488	Treatment of cutaneous and/or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (cGVHD) by a total nodal irradiation (TNI). <b>2017</b> , 31, e12923		1
1487	Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1208-1214	4.7	24
1486	Characteristics of Submacular Hemorrhages in Age-Related Macular Degeneration. <b>2017</b> , 94, 556-563		9
1485	Central and peripheral nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation. <b>2017</b> , 307, 74-81		12
1484	Short article: Capsule endoscopy in graft-versus-host disease. <b>2017</b> , 29, 423-427		8
1483	Interrater and Test-Retest Reliability of the Beery Visual-Motor Integration in Schoolchildren. <b>2017</b> , 94, 598-605		8
1482	Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease. <b>2017</b> , 177, e206-e208		18
1481	A Review of Ocular Graft-Versus-Host Disease. <b>2017</b> , 94, 545-555		34
1480	Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <b>2017</b> , 19, e12717		15
1479	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1549-1554	4.7	21
1478	B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. <b>2017</b> , 52, 1010-1015		18
1477	[Ocular graft versus host disease : Corneal complications]. <b>2017</b> , 114, 697-702		2
1476	A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease. <b>2017</b> , 36, 799-804		15
1475	Novel targets in the treatment of chronic graft-versus-host disease. <b>2017</b> , 31, 543-554		39
1474	Imaging of late complications of cancer therapy in children. <b>2017</b> , 47, 254-266		6
1473	Rehabilitation in Chronic Graft-Versus-Host Disease. <b>2017</b> , 28, 143-151		3



1472	Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1491-1497	4-7	8
1471	A possible role of low regulatory T cells in anti-acetylcholine receptor antibody positive myasthenia gravis after bone marrow transplantation. <b>2017</b> , 17, 93		1
1470	Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1541-1548	4-7	10
1469	Diagnosis and treatment of chronic graft-versus-host disease. <b>2017</b> , 334-347		
1468	The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. <b>2017</b> , 101, e34-e38		12
1467	Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg. <b>2017</b> , 7, 3603		6
1466	Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice. <b>2017</b> , 31, 1417-1426		18
1465	Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1485-1490	4-7	7
1464	Graft-versus-Host Disease of the Gut: A Histologic Activity Grading System and Validation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1573-1579	4-7	12
1463	Dynamics of epigenetic age following hematopoietic stem cell transplantation. <b>2017</b> , 102, e321-e323		21
1462	Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide. <b>2017</b> , 10, 79-84		12
1461	Diarrhea after allogeneic stem cell transplantation: beyond graft-versus-host disease. <b>2017</b> , 29, 495-502		17
1460	Evolving concepts in prognostic scoring of chronic GvHD. <b>2017</b> , 52, 1361-1366		5
1459	Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. <b>2017</b> , 52, 1138-1143		17
1458	Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report. <b>2017</b> , 58, 2770-2771		0
1457	Atlas of Graft-versus-Host Disease. <b>2017</b> ,		1
1456	Classification systems for chronic graft-versus-host disease. <b>2017</b> , 129, 30-37		139
1455	How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <b>2017</b> , 129, 448-455		58

1454	Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. <b>2017</b> , 129, 13-21	148
1453	Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant. <b>2017</b> , 52, 625-626	16
1452	Good responses but high TRM in adult patients after MSC therapy for GvHD. <b>2017</b> , 52, 606-608	37
1451	Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications. <b>2017</b> , 14, 997-1006	6
1450	Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. <b>2017</b> , 14, 711-726	60
1449	Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. <b>2017</b> , 52, 1623-1628	12
1448	Pulmonary Injury and Chronic Graft-versus-Host Disease: Do We Miss the Signs and Symptoms?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1605-1606	4-7
1447	In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. <b>2017</b> , 17, 1401-1415	8
1446	Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2017</b> , 38, 607-621	28
1445	In Vivo Confocal Microscopy Evaluation of Ocular Surface with Graft-Versus-Host Disease-Related Dry Eye Disease. <b>2017</b> , 7, 10720	32
1444	Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease. <b>2017</b> , 195, 781-788	10
1443	Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 2192-2198	4-7 14
1442	Outcomes of Hematopoietic Stem Cell Transplantation at a Limited-Resource Center in Mexico Are Comparable to Those in Developed Countries. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1998-2003	4-7 7
1441	Changes of meibomian glands in the early stage of post hematopoietic stem cell transplantation. <b>2017</b> , 163, 85-90	14
1440	Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT. <b>2017</b> , 96, 1525-1531	7
1439	Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1949-1954	4-7 3
1438	Proinflammatory Dual Receptor T Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1852-1860	4-7 4
1437	A review of late complications of allogeneic hematopoietic stem cell transplantations. <b>2017</b> , 31, e13062	16

1436	Late respiratory effects of cancer treatment. <b>2017</b> , 11, 197-204		1
1435	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 2127-2136	4-7	10
1434	Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD. <b>2017</b> , 40, 447-450		6
1433	Changes in protein serum levels during stem cell transplantation. <b>2017</b> , 47, 711-718		1
1432	Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. <b>2017</b> , 318, 557-566		63
1431	CAR emissions: cytokines tell the story. <b>2017</b> , 130, 2238-2240		8
1430	Chronic GVHD: progress in salvage treatment?. <b>2017</b> , 130, 2237-2238		2
1429	Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <b>2017</b> , 37, 693-698		4
1428	Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1722-1728	4-7	12
1427	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1736-1743	4-7	26
1426	Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia. <b>2017</b> , 33, 525-533		3
1425	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1744-1748	4-7	7
1424	Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study. <b>2017</b> , 19, 927-936		37
1423	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 285-292	4-7	16
1422	Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD. <b>2017</b> , 52, 101-106		22
1421	Cutaneous manifestations of graft-versus-host disease: role of the dermatologist. <b>2017</b> , 56, 131-140		20
1420	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 211-234	4-7	206
1419	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 67-74	4-7	18

1418	[Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC)]. <b>2017</b> , 104, S145-S168	0
1417	Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. <b>2017</b> , 377, 2565-2579	261
1416	[Myelodysplastic syndrome, acute leukemia and stem cell transplantation]. <b>2017</b> , 76, 26-32	3
1415	Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1587-1592	34
1414	Atopic Dermatitis-like Graft-versus-host Disease and Lichen Planus-like Graft-versus-host Disease: Alterations in Skin Barrier Function and Related Molecules. <b>2017</b> , 130, 1459-1466	2
1413	TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease. <b>2017</b> , 17, 144-151	15
1412	B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2016</b> , 7, 660	7
1411	Pathophysiology of GvHD and Other HSCT-Related Major Complications. <b>2017</b> , 8, 79	81
1410	Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation. <b>2017</b> , 8, 810	6
1409	Serum Vitamin A Levels May Affect the Severity of Ocular Graft-versus-Host Disease. <b>2017</b> , 4, 67	9
1408	Reduced Expression of VAMP8 in Lacrimal Gland Affected by Chronic Graft-versus-Host Disease. <b>2017</b> , 2017, 1639012	2
1407	Long-Term Follow-Up Program and Chronic Graft-versus-Host Disease. <b>2017</b> , 6, 84-97	1
1406	Chronic Graft-versus-host Disease Presenting with Multiple Punctate Intracranial Lesions on Contrast-enhanced Magnetic Resonance Imaging. <b>2017</b> , 56, 363-368	5
1405	Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. <b>2017</b> , 12, e0185210	4
1404	Clinical and radiological characteristics of patients with late-onset severe restrictive lung defect after hematopoietic stem cell transplantation. <b>2017</b> , 17, 123	14
1403	Prehematopoietic Stem Cell Transplantation Tear Cytokines as Potential Susceptibility Biomarkers for Ocular Chronic Graft-Versus-Host Disease. <b>2017</b> , 58, 4836-4846	8
1402	The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease. <b>2017</b> , 5,	15
1401	Chronic Graft-versus-Host Disease: Consensus, Challenges, and Controversies. 163-176	1

1400	Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature. <b>2018</b> , 10, e2018005		7
1399	Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation. <b>2017</b> , 34, 1-9		32
1398	Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. <b>2017</b> , 35, 3143-3152		20
1397	Pulmonary Complications of Malignancies and Blood and Marrow Transplantation. <b>2018</b> , 51-77		1
1396	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1449-1454	4-7	25
1395	Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1727-1732	4-7	7
1394	Successful Treatment of Adolescents and Young Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia by Novel L-Asparaginase-Intensified Induction Therapy and Cord Blood Transplantation: A Single-Center Decade Report. <b>2018</b> , 7, 389-394		1
1393	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft--host disease: low incidence of lower gastrointestinal tract disease. <b>2018</b> , 103, 717-727		31
1392	Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine. <b>2018</b> , 40, e220-e224		0
1391	Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1471-1475	4-7	17
1390	Ruxolitinib for steroid-refractory graft-versus-host disease: A case series. <b>2018</b> , 36, 611		2
1389	Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease. <b>2018</b> , 58, 1494-1499		4
1388	Chemokines: a novel chronic GVHD target. <b>2018</b> , 131, 1636-1638		
1387	Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. <b>2018</b> , 51,		33
1386	Inflammation-Associated Cytokines IGFBP1 and RANTES Impair the Megakaryocytic Potential of HSCs in PT Patients after Allo-HSCT. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1142-1151	4-7	7
1385	B-cell targeting in chronic graft-versus-host disease. <b>2018</b> , 131, 1399-1405		32
1384	Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. <b>2018</b> , 53, 826-831		55
1383	Biomarkers in chronic graft-versus-host disease: quo vadis?. <b>2018</b> , 53, 832-837		36

1382	N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. <b>2018</b> , 93, 931-942		16
1381	Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH' trials. <b>2018</b> , 10, 391-402		58
1380	[Cutaneous graft-versus-host disease]. <b>2018</b> , 69, 109-115		1
1379	Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China. <b>2018</b> , 8, 2479		12
1378	Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. <b>2018</b> , 50, 241-245		1
1377	Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. <b>2018</b> , 53, 863-872		22
1376	Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, S7-S14	4-7	8
1375	Chronic graft versus host disease presenting as lichen planus pigmentosus. <b>2018</b> , 53, 1048-1050		1
1374	Pulmonary Complications of Non-Pulmonary Pediatric Disorders. <b>2018</b> ,		
1373	Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. <b>2018</b> , 131, 1743-1754		13
1372	Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment. <b>2018</b> , 53, 334-338		0
1371	Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. <b>2018</b> , 53, 490-494		13
1370	Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. <b>2018</b> , 131, 1476-1485		30
1369	Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. <b>2018</b> , 131, 2074-2085		20
1368	Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation. <b>2018</b> , 154, 157-168		12
1367	Long-Term Topical Diquafosol Tetrasodium Treatment of Dry Eye Disease Caused by Chronic Graft-Versus-Host Disease: A Retrospective Study. <b>2018</b> , 44 Suppl 2, S215-S220		5
1366	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 997-1004	4-7	12
1365	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 956-963	4-7	12

1364	The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1125-1134	4-7	43
1363	Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia. <b>2018</b> , 97, 497-507		7
1362	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1013-1021	4-7	35
1361	Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. <b>2018</b> , 53, 503-506		16
1360	Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. <b>2018</b> ,		1
1359	Skin Tumors and Reactions to Cancer Therapy in Children. <b>2018</b> ,		
1358	Topical vitamin D analog for chronic graft versus host disease of the skin. <b>2018</b> , 53, 628-633		3
1357	Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. <b>2018</b> , 53, 417-421		1
1356	Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 542-548	4-7	6
1355	CD34 Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome . <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 964-972	4-7	15
1354	Hematopoietic stem cell transplantation in Niemann-Pick disease type B monitored by chitotriosidase activity. <b>2018</b> , 65, e26811		2
1353	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1906-1913	4-7	13
1352	Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease. <b>2018</b> , 142, 1098-1105		2
1351	Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1415-1423	4-7	6
1350	Minimizing Disability from Graft-Versus-Host Disease. <b>2018</b> , 6, 131-135		
1349	Stromal progenitor cell modulation by thalidomide in the treatment of oral chronic graft-versus-host disease. <b>2018</b> , 20, 755-758		1
1348	Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability. <b>2018</b> , 62,		33
1347	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. <b>2018</b> , 5, e161-e169		42

1346	Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. <b>2018</b> , 79, 230-237		3
1345	Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1920-1927	4-7	21
1344	Vaccination post-allogeneic hematopoietic stem cell transplantation: what is feasible?. <b>2018</b> , 17, 299-309		11
1343	The European Blood and Marrow Transplantation Textbook for Nurses. <b>2018</b> ,		10
1342	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1733-1740	4-7	11
1341	Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib. <b>2018</b> , 53, 1255-1262		8
1340	Subtarsal Fibrosis Is Associated With Ocular Surface Epitheliopathy in Graft-Versus-Host Disease. <b>2018</b> , 189, 102-110		21
1339	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. <b>2018</b> , 65, e27034		17
1338	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. <b>2018</b> , 97, 1209-1217		6
1337	Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome. <b>2018</b> , 36, 276-284		9
1336	Confocal endomicroscopy in diagnosis of intestinal chronic graft-versus-host disease. <b>2018</b> , 36, 291-298		1
1335	Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment. <b>2018</b> , 19, 33-50		63
1334	Infection with a respiratory virus before hematopoietic cell transplantation is associated with alloimmune-mediated lung syndromes. <b>2018</b> , 141, 697-703.e8		10
1333	'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <b>2018</b> , 53, 58-63		4
1332	Functional Role of Lacrimal Gland Fibroblasts in a Mouse Model of Chronic Graft-Versus-Host Disease. <b>2018</b> , 37, 102-108		7
1331	Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. <b>2018</b> , 124, 286-296		20
1330	Mycobacterium abscessus and massiliense lung infection during macrolide treatment for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. <b>2018</b> , 24, 78-81		8
1329	Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 119-126	4-7	25



1328	Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 194-199	4-7	31
1327	Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 19-26	4-7	20
1326	Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 32-42	4-7	21
1325	Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 549-554	4-7	26
1324	Development of a novel histologic diagnostic algorithm for hepatic graft-versus-host disease. <b>2018</b> , 31, 442-451		6
1323	Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study. <b>2018</b> , 24, 580-590		8
1322	Poor Adherence Is Associated with More Infections after Pediatric Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 381-385	4-7	14
1321	Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 267-275	4-7	19
1320	Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 529-536	4-7	51
1319	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 359-365	4-7	14
1318	Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma. <b>2018</b> , 36, 363-365		2
1317	A case of red lunulae after haematopoietic stem cell transplantation. <b>2018</b> , 28, 407-409		
1316	JSHCT meeting symposium report: current status and future perspective of chronic graft-versus-host disease. <b>2018</b> , 7, 56-63		
1315	Contemporary analysis of functional immune recovery to opportunistic and vaccine-preventable infections after allogeneic haemopoietic stem cell transplantation. <b>2018</b> , 7, e1040		3
1314	ORAL CYCLOSPORINE AS AN ALTERNATIVE FOR INITIAL STANDARD PROPHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION WHEN INTRAVENOUS FORMULATION IS UNAVAILABLE. <b>2018</b> , 11, 108		
1313	Scleral Lenses Therapy for Ocular Graft-Versus-Host Disease. <b>2018</b> , 09,		
1312	Morbidity and Mortality Associated With Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplant: Too Little Defense or Harmful Immunity?. <b>2018</b> , 9, 2795		6
1311	Sjögren's Syndrome, Non-Sjögren's Syndrome, and Graft-Versus-Host Disease Related Dry Eye. <b>2018</b> , 59, DES71-DES79		15

1310	Novel Cellular Therapeutic Approaches for the Prevention and Management of Graft-Versus-Host Disease. <b>2018</b> , 4, 318-326	
1309	Mini photopheresis for refractory chronic graft-versus-host disease in children and adolescents. <b>2018</b> , 58, 2495-2500	2
1308	Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT. <b>2018</b> , 13, e0204136	3
1307	eGVHD App: a new tool to improve graft--host disease assessment. <b>2018</b> , 103, 1583-1585	
1306	Transplantation Pathology. <b>2018</b> , 880-965	2
1305	Therapeutic Apheresis for Hematologic Emergencies. <b>2018</b> , 341-361	
1304	Hematologic Challenges in the Critically Ill. <b>2018</b> ,	0
1303	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <b>2018</b> , 9, 2207	9
1302	How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. <b>2018</b> , 2, 2012-2019	49
1301	Inflammatory myopathies after allogeneic stem cell transplantation. <b>2018</b> , 58, 790-795	15
1300	Extended Abstract: Lung Injury after Allogeneic Hematopoietic Cell Transplantation. <b>2018</b> , 18, S128-S130	
1299	Manifestation of Clinical Categories of Ocular Graft-versus-Host Disease. <b>2018</b> , 2018, 6430953	12
1298	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <b>2018</b> , 18, e529-e535	
1297	Pericarditis in Patients With Chronic Graft-vs-Host Disease. <b>2018</b> , 50, 2218-2222	6
1296	Extracorporeal Photopheresis-An Overview. <b>2018</b> , 5, 236	37
1295	Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease. <b>2018</b> , 234, 23-30	4
1294	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1203-1208	4-7 1
1293	Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD. <b>2018</b> , 16, 377-381	12

1292	Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. <b>2018</b> , 101, 305-317		29
1291	Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. <b>2018</b> , 53, 1560-1567		4
1290	[Pyoderma gangrenosum following hematopoietic stem cell transplantation]. <b>2018</b> , 145, 445-450		1
1289	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2277-2284	4-7	11
1288	Lung histopathology of non-infectious pulmonary complications after allogeneic haematopoietic stem cell transplantation. <b>2018</b> , 73, 832-842		13
1287	A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801. <b>2018</b> , 103, 1915-1924		21
1286	Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease. <b>2018</b> , 108, 298-305		6
1285	[Cutaneous and systemic T-cell lymphoma treated with haploidentical bone marrow transplantation]. <b>2018</b> , 145, 439-444		2
1284	Complications After Hematopoietic Cell Transplantation. <b>2018</b> , 1669-1684.e2		0
1283	Vanishing Bile Ducts in the Long Term after Pediatric Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2250-2258	4-7	3
1282	Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2450-2458	4-7	6
1281	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2501-2508	4-7	15
1280	Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report. <b>2018</b> , 89, 113-117		2
1279	Timepoints of vancomycin-resistant Enterococcus colonization predict outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation. <b>2018</b> , 101, 620		
1278	Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. <b>2017</b> , 8, 1979		7
1277	Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1836-1840	4-7	5
1276	Cellular Therapy. <b>2018</b> , 401-421		
1275	Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. <b>2018</b> , 72, 20-26		23

1274	Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin. <b>2018</b> , 53, 145-151	2
1273	<i>Stenotrophomonas maltophilia</i> colonization during allogeneic hematopoietic stem cell transplantation is associated with impaired survival. <b>2018</b> , 13, e0201169	7
1272	Allogeneic HSCT transfers wild-type cystinosin to nonhematological epithelial cells in cystinosis: First human report. <b>2018</b> , 18, 2823-2828	13
1271	A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. <b>2018</b> , 97, 1122-1129	7
1270	Acute graft v host disease: developing an extracorporeal photopheresis outreach service. <b>2018</b> , 27, 488-492	
1269	Chronic graft versus host disease is associated with erectile dysfunction in allogeneic hematopoietic stem cell transplant patients: a single-center experience. <b>2018</b> , 59, 2719-2722	2
1268	Autologous graft-versus-host disease with combined immune checkpoint blockade. <b>2018</b> , 101, 275-277	
1267	Myasthenia Gravis Presenting as Graft versus Host Disease after Allogeneic Blood Stem Cell Transplant. <b>2018</b> , 2018, 7296930	
1266	Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <b>2018</b> , 323, 115-118	8
1265	Tear Film Proteomics Reveal Important Differences Between Patients With and Without Ocular GvHD After Allogeneic Hematopoietic Cell Transplantation. <b>2018</b> , 59, 3521-3530	15
1264	Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose. <b>2018</b> , 93, 1368-1375	10
1263	Amniotic membrane transplantation-a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease. <b>2018</b> , 53, 1466-1469	14
1262	Loss of Intrahepatic Bile Ducts. <b>2018</b> , 433-444	
1261	EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <b>2018</b> , 53, 1401-1415	120
1260	Permanent alopecia as a manifestation of chronic graft-versus-host disease of the scalp: clinical, dermoscopic and histopathological observations. <b>2018</b> , 43, 948-949	2
1259	The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. <b>2018</b> , 103, 1698-1707	15
1258	Higher CD45RA Regulatory T Cells in the Graft Improves Outcome in Younger Patients Undergoing T Cell-Replete Haploidentical Transplantation: Where Donor Age Matters. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2025-2033	4-7 17
1257	Hair and Scalp Disorders Associated With Systemic Disease (Secondary Alopecia). <b>2019</b> , 183-192	

1256	Whole-Body Lung Function Test-Derived Outcome Predictors in Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 129-136	4-7	4
1255	Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. <b>2019</b> , 54, 383-392		11
1254	Solid organ transplantation following allogeneic haematopoietic cell transplantation: experience from a referral organ transplantation center and systematic review of literature. <b>2019</b> , 54, 190-203		5
1253	Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. <b>2019</b> , 54, 76-84		7
1252	Quantity and Quality Reconstitution of NKG2A Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1-11	4-7	15
1251	Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies. <b>2019</b> , 98, 185-193		12
1250	Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease. <b>2019</b> , 54, 35-43		2
1249	Two enemies, one fight: An update of oral cancer in patients with Fanconi anemia. <b>2019</b> , 125, 3936-3946		4
1248	A Practical Guide to Gynecologic and Reproductive Health in Women Undergoing Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e331-e343	4-7	11
1247	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2468-2473	4-7	4
1246	Advances in the treatment of chronic graft-versus-host disease. <b>2019</b> , 2, e55		
1245	Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2338-2349	4-7	5
1244	Trajectory of lung function to pleuroparenchymal fibroelastosis late after haematopoietic stem-cell transplantation. <b>2019</b> , 28, 100915		
1243	Vulvovaginal graft-versus-host disease: a review. <b>2019</b> , 22, 603-609		1
1242	Review of Graft-Versus-Host Disease. <b>2019</b> , 37, 569-582		41
1241	Oral Complications of Chronic Graft-Versus-Host Disease. <b>2019</b> , 2019,		15
1240	Allogeneic stem cell transplantation for myelofibrosis patients aged $\geq$ 5 years. <b>2019</b> , 103, 370-378		4
1239	Refractory autoimmune haemolytic anaemia following allogeneic haematopoietic stem cell transplantation: successful treatment of rituximab. <b>2019</b> , 47, 3320-3331		1

1238	Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2408-2415	4-7	5
1237	Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients. <b>2019</b> , 94, 1072-1080		3
1236	Allogeneic Bone Marrow Transplants for Pediatric Severe Aplastic Anemia: Real-world Data comparing Matched Related and Unrelated Donors in a Developing Country. Retrospective study on behalf of the Pediatric Hematopoietic Stem Cell Transplant Working Group of the Brazilian Bone Marrow Transplantation Society (SBTMO) and the Brazil-Seattle Consortium (Gedeco). <b>2019</b> , 23, e13552		3
1235	A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation. <b>2019</b> , 110, 635-639		9
1234	An 8-step framework for implementing time-driven activity-based costing in healthcare studies. <b>2019</b> , 20, 1133-1145		15
1233	In Vivo Confocal Microscopy Evaluation in Dry Eye and Related Diseases. <b>2019</b> , 7, 187-195		2
1232	A general practitioner's guide to hematopoietic stem-cell transplantation. <b>2019</b> , 26, 187-191		22
1231	Cutaneous Chronic Graft Versus Host Disease in a Symmetric Distribution. <b>2019</b> , 11, e4614		
1230	Rotavirus infection following post-transplantation cyclophosphamide based haploidentical hematopoietic cell transplantation in children is associated with hemophagocytic syndrome and high mortality. <b>2019</b> , 21, e13136		1
1229	Other Inflammatory Disorders of Duodenum. <b>2019</b> , 239-263		
1228	Diverse Activity of IL-17 Cells in Chronic Skin and Mucosa Graft-Versus-Host Disease. <b>2019</b> , 67, 311-323		2
1227	The Liver in Systemic Illness. <b>2019</b> , 361-396		0
1226	Drugs as a Frequent Cause of Acute Rash in Patients after CD34-Selected Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2172-2180	4-7	2
1225	American Thoracic Society 2019 Pediatric Core Curriculum. <b>2019</b> , 54, 1880-1894		
1224	Monitoring lung function in patients with chronic graft versus host disease: a pilot study. <b>2019</b> , 28, 1196-1200		1
1223	The impact of pretransplant malnutrition on allogeneic hematopoietic stem cell transplantation outcomes. <b>2019</b> , 33, 213-219		4
1222	Inpatient Management of Mucocutaneous GVHD. <b>2019</b> , 8, 258-278		1
1221	Histologic and clinical cross-sectional study of chronic hair loss in patients with cutaneous chronic graft-versus-host disease. <b>2019</b> , 81, 1134-1141		2

1220	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. <b>2019</b> , 103, 597-606		6
1219	[Post-transplant pulmonary complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. <b>2019</b> , 106, S10-S17		
1218	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. <b>2019</b> , 103, 510-518		10
1217	Lung evaluation in 10-year survivors of pediatric allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 178, 1833-1839		4
1216	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. <b>2019</b> , 15, 3531-3545		27
1215	The therapeutic application of mesenchymal stem cells at the ocular surface. <b>2019</b> , 17, 198-207		14
1214	Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. <b>2019</b> , 24, 459-466		20
1213	How I treat refractory chronic graft-versus-host disease. <b>2019</b> , 133, 1191-1200		40
1212	Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement. <b>2019</b> , 54, 1148-1150		2
1211	Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. <b>2019</b> , 54, 1158-1160		17
1210	Pathology of Graft vs. Host Disease. <b>2019</b> ,		
1209	Evolutions in the Clinical Management of GVHD. <b>2019</b> , 11-20		
1208	Phenotypical diversity of airway morphology in chronic lung graft vs. host disease after stem cell transplantation. <b>2019</b> , 32, 817-829		6
1207	Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 834-841	4-7	6
1206	Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 975-980	4-7	20
1205	ENDOCRINE COMPLICATIONS IN PATIENTS WITH GVHD. <b>2019</b> , 25, 485-490		1
1204	G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2040-2044	4-7	3
1203	Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. <b>2019</b> , 98, 2163-2177		15

1202	High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1970-1974	4-7	5
1201	Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use Correlates with the Occurrence of Intestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1933-1943	4-7	24
1200	Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients. <b>2019</b> , 7, 171		13
1199	T memory stem cells after allogeneic haematopoietic cell transplantation: unique long-term kinetics and influence of chronic graft-versus-host disease. <b>2019</b> , 186, 866-878		5
1198	Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1803-1809	4-7	11
1197	Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation. <b>2019</b> , 1-17		
1196	Impact of Preemptive Granulocyte Infusions During Febrile Neutropenia in Patients Colonized with Carbapenem-Resistant Gram-Negative Bacteria Undergoing Haploidentical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1621-1628	4-7	3
1195	Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host disease. <b>2019</b> , 59, 2636-2642		6
1194	Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma. <b>2019</b> , 98, 1743-1753		1
1193	Lipocalin-2 levels in acute and chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 74, 25-32.e1		
1192	Oral mucosal changes associated with primary diseases in other body systems. <b>2019</b> , 80, 28-48		9
1191	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. <b>2019</b> , 54, 1815-1826		41
1190	Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. <b>2019</b> , 54, 1805-1814		16
1189	Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis. <b>2019</b> , 44, 84-91		5
1188	Lung clearance index for early detection of pulmonary complications after allo-HSCT in children. <b>2019</b> , 54, 1029-1038		6
1187	Patterns of onset and outcome of cryptogenic organizing pneumonia after allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 109, 700-710		1
1186	Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. <b>2019</b> , 134, 304-316		31
1185	Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis. <b>2019</b> , 74, 33-41		3



1184	Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy. <b>2019</b> , 60, 2733-2743	12
1183	Feasibility of extracorporeal photopheresis in pediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation. <b>2019</b> , 23, e13416	3
1182	MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. <b>2019</b> , 3, 83-95	27
1181	Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. <b>2019</b> , 155, 833-837	2
1180	Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <b>2019</b> , 19, 345-355.e7	1
1179	Donor-derived CD4/CCR7 T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide. <b>2019</b> , 54, 1686-1693	2
1178	Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. <b>2019</b> , 14, e0213913	7
1177	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1407-1415	17
1176	Graft-Versus-Host Disease. <b>2019</b> , 195-208	
1175	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. <b>2019</b> , 6, e183-e193	62
1174	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. <b>2019</b> , 54, 1730-1737	15
1173	Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation. <b>2019</b> , 143, 1131-1143	5
1172	B cells in chronic graft-versus-host disease. <b>2019</b> , 80, 393-399	24
1171	Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease. <b>2019</b> , 10, 334	8
1170	Graft versus host disease: a pediatric perspective. <b>2019</b> , 14, 89-99	0
1169	VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients. <b>2019</b> , 9, e026093	6
1168	Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1450-1455	4-7 6
1167	Clinical Ophthalmic Oncology. <b>2019</b> ,	2

1166	A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. <b>2019</b> , 12, 311-323	10
1165	Ruxolitinib for Therapy of Graft-versus-Host Disease. <b>2019</b> , 2019, 8163780	11
1164	Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies. <b>2019</b> , 17, 589-614	35
1163	Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation. <b>2019</b> , 78, 461-467	2
1162	Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. <b>2019</b> , 98, 1485-1493	15
1161	Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. <b>2019</b> , 12, 295-309	6
1160	Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle. <b>2019</b> , 257, 1341-1351	36
1159	Shaping of CD56 Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. <b>2019</b> , 10, 547	7
1158	Crowdsourcing to delineate skin affected by chronic graft-vs-host disease. <b>2019</b> , 25, 572-577	1
1157	Female genital tract chronic graft-versus-host disease: A narrative review. <b>2019</b> , 41, 69-75	4
1156	Diagnosing and managing bronchiolitis obliterans in children. <b>2019</b> , 13, 481-488	21
1155	Manifestations of Chronic GVHD in Other Organ Systems. <b>2019</b> , 237-244	
1154	Clinical Immunology in Diagnoses of Maxillofacial Disease. <b>2019</b> , 315-339	
1153	Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <b>2019</b> , 9, 2046	5
1152	Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model. <b>2019</b> , 41, 584-596	11
1151	Mucosal Chronic GVHD Affecting the Oral Pharyngeal, Esophageal, and Anogenital Regions. <b>2019</b> , 143-156	
1150	New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1225-1231	4-7 7
1149	Commensal microflora in human conjunctiva; characteristics of microflora in the patients with chronic ocular graft-versus-host disease. <b>2019</b> , 17, 265-271	25

1148	First-Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell Transplantation. <b>2019</b> , 200, 63-74	21
1147	pldist: ecological dissimilarities for paired and longitudinal microbiome association analysis. <b>2019</b> , 35, 3567-3575	9
1146	Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation. <b>2019</b> , 54, 1614-1624	6
1145	Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation. <b>2019</b> , 54, 1651-1661	6
1144	Clinical Symptoms and Signs of Dry Eye Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2019</b> , 60, 1148	
1143	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <b>2019</b> , 3, 2550-2561	19
1142	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <b>2019</b> , 3, 1441-1449	7
1141	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <b>2019</b> , 3, 2764-2777	7
1140	Joint effort to target the orphan of the orphan. <b>2019</b> , 134, 224-225	
1139	Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. <b>2019</b> , 3, 230-236	11
1138	Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin. <b>2019</b> , 3, 1394-1405	5
1137	Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. <b>2019</b> , 3, 2218-2229	13
1136	A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD. <b>2019</b> , 3, 2128-2143	8
1135	Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. <b>2019</b> , 3, 3351-3359	13
1134	Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT. <b>2019</b> , 3, 3287-3296	0
1133	National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution. <b>2019</b> , 10, 1879	7
1132	Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. <b>2019</b> , 2, e62	2
1131	Allogeneic Hematopoietic Cell Transplantation in Thalassemia Major: A Single-center Retrospective Analysis From India. <b>2019</b> , 41, e296-e301	3

1130	Structural Differences in Meibum From Donors After Hematopoietic Stem Cell Transplantations. <b>2019</b> , 38, 1169-1174			10
1129	Current status of graft-versus-host disease after intestinal transplantation. <b>2019</b> , 24, 199-206			20
1128	Favorable Outcome of Lung Transplantation for Severe Pulmonary Graft Versus Host Disease: An Australian Multicenter Case Series. <b>2019</b> , 103, 2602-2607			3
1127	Association between chronic bacterial airway infection and prognosis of bronchiolitis obliterans syndrome after hematopoietic cell transplantation. <b>2019</b> , 98, e13951			5
1126	Possible role of highly activated mucosal NK cells against viral respiratory infections in children undergoing haematopoietic stem cell transplantation. <b>2019</b> , 9, 18792			2
1125	The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study. <b>2019</b> , 49, 213-222			8
1124	Limbal and Conjunctival Epithelial Thickness in Ocular Graft-Versus-Host Disease. <b>2019</b> , 38, 1286-1290			1
1123	Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis. <b>2019</b> , 9, 20402			5
1122	Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 183-190	4-7		1
1121	Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 293-300	4-7		6
1120	The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 279-286	4-7		4
1119	Longstanding alopecia and nail dystrophy are associated with more severe overall chronic graft-versus-host disease in adults. <b>2019</b> , 54, 469-472			3
1118	Comparison among different diagnostic criteria for chronic ocular graft-versus-host disease applied with and without pre-transplant ophthalmological examination. <b>2019</b> , 33, 154-160			6
1117	Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 265-269	4-7		44
1116	Marked infiltration of neutrophils at the upper palpebral conjunctiva in patients with chronic graft-versus-host disease. <b>2019</b> , 17, 295-302			2
1115	Fludarabine/Melphalan 100 mg/m Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1116-1121	4-7		3
1114	Biomarker profiling of steroid-resistant chronic GvHD patients undergoing extracorporeal photopheresis demonstrates high ST2 levels at treatment onset and decline during therapy. <b>2019</b> , 2, e32			1
1113	Graft-versus-host disease. <b>2019</b> , 152, 22-28			9

1112	The Association of Performance Status and Disease Severity in Patients With Chronic Graft-vs-Host Disease. <b>2019</b> , 100, 606-612		5
1111	Rabbit Antithymocyte Globulin Serum Levels: Factors Impacting the Levels and Clinical Outcomes Impacted by the Levels. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 639-647	4-7	9
1110	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <b>2019</b> , 54, 1254-1265		25
1109	Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency. <b>2019</b> , 7, 848-855		39
1108	Graft-versus-host disease. <b>2019</b> , 152, 22-28		0
1107	Renal dysfunction within 90 days of FluBu4 predicts early and late mortality. <b>2019</b> , 54, 980-986		2
1106	Reduced-Toxicity Myeloablative Conditioning Consisting of Fludarabine/Busulfan/Low-Dose Total Body Irradiation/Granulocyte Colony-Stimulating Factor-Combined Cytarabine in Single Cord Blood Transplantation for Elderly Patients with Nonremission Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 764-770	4-7	13
1105	Retrospective analysis of thiamine deficiency in allogeneic stem cell transplant patients. <b>2019</b> , 98, 1499-1500		3
1104	Vitamin D: is it important in haematopoietic stem cell transplantation? A review. <b>2019</b> , 54, 810-820		18
1103	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. <b>2019</b> , 25, 1737-1748		13
1102	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e46-e54	4-7	13
1101	Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1019-1027		14
1100	Disability related to chronic graft --host disease after alternative donor hematopoietic cell transplantation. <b>2019</b> , 104, 835-843		12
1099	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 466-473	4-7	3
1098	Medical Course and Complications After Hematopoietic Cell Transplantation. <b>2019</b> , 417-438		
1097	Hematopoietic Cell Transplantation. <b>2019</b> , 487-502		0
1096	Onychoscopy of non-infectious nail abnormalities in patients after allogeneic haematopoietic stem cell transplantation. <b>2019</b> , 33, 637-642		4
1095	Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. <b>2019</b> , 98, 491-500		5

1094	CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 673-682	4-7	18
1093	Premalignant Conditions of the Oral Cavity. <b>2019</b> ,		
1092	Non-invasive measurement of sclerosis in cutaneous cGVHD patients with the handheld device Myoton: a cross-sectional study. <b>2019</b> , 54, 616-619		6
1091	Expanding Therapeutic Opportunities for Hematopoietic Stem Cell Transplantation: T Cell Depletion as a Model for the Targeted Allograft. <b>2019</b> , 70, 381-393		4
1090	Negative impact of chronic graft-versus-host disease and glucocorticoid on the recovery of physical function after allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 54, 994-1003		12
1089	Dermatologic Conditions of the Early Post-Transplant Period in Hematopoietic Stem Cell Transplant Recipients. <b>2019</b> , 20, 55-73		2
1088	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 515-521	4-7	16
1087	Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 13, 105-119		15
1086	Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 800-809	4-7	8
1085	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <b>2019</b> , 54, 662-673		22
1084	A retrospective comparison of allogeneic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. <b>2019</b> , 54, 1208-1217		16
1083	Mesenchymal Stem Cell Therapy in Graft Versus Host Disease. <b>2019</b> , 111-141		
1082	Machine learning reveals chronic graft--host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. <b>2019</b> , 104, 189-196		33
1081	T-cell receptor-repertoire of CD8+ T cells following allogeneic stem cell transplantation using next-generation sequencing. <b>2019</b> , 104, 622-631		14
1080	Early initiation of extracorporeal photochemotherapy increases response for chronic graft versus host disease following steroid failure. <b>2019</b> , 26, 32-37		3
1079	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. <b>2020</b> , 55, 349-355		8
1078	Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 278-284	4-7	6
1077	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 58-65	4-7	7

1076	Long-Term Utilization Patterns of Topical Therapy and Clinical Outcomes of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 373-379	4-7	2
1075	Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. <b>2020</b> , 6, e192974		9
1074	Donor single nucleotide polymorphism in ACAT1 affects the incidence of graft-versus-host disease after bone marrow transplantation. <b>2020</b> , 111, 112-119		1
1073	Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). <b>2020</b> , 95, 28-37		17
1072	Corneal higher-order aberrations in eyes with chronic ocular graft-versus-host disease. <b>2020</b> , 18, 98-107		9
1071	Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?. <b>2020</b> , 55, 505-522		9
1070	The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. <b>2020</b> , 98, 75-87		11
1069	Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin. <b>2020</b> , 17, 380-394		20
1068	Cyclosporine A for the Prevention of Ocular Graft versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Is Safe and Feasible. <b>2020</b> , 143, 425-431		1
1067	Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease. <b>2020</b> , 55, 1194-1196		13
1066	R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 683-690	4-7	5
1065	Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 94-106	4-7	15
1064	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 772-777	4-7	9
1063	Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 351-357	4-7	9
1062	Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 568-580	4-7	4
1061	GVHD prophylaxis by tacrolimus and mini-MTX in single-unit CBT: a single institute experience. <b>2020</b> , 111, 278-283		6
1060	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 392-400	4-7	11
1059	Common and critical inflammatory dermatoses every pathologist should know. <b>2020</b> , 33, 107-117		3

1058	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. <b>2020</b> , 55, 763-772		3
1057	Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. <b>2020</b> , 20, 677-688		3
1056	Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation. <b>2020</b> , 111, 120-130		5
1055	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <b>2020</b> , 104, 36-45		2
1054	Evaluation of treatment response in oral chronic graft-versus-host patients by power doppler ultrasound: a prospective study. <b>2020</b> , 49, 20190295		0
1053	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 358-366	4-7	20
1052	Sclerodermalike syndromes: Great imitators. <b>2020</b> , 38, 235-249		9
1051	Increased regulatory T cells and eosinophils characterize atopic dermatitis-like graft-versus-host disease compared with lichen planus-like graft-versus-host disease. <b>2020</b> , 83, 824-831		0
1050	Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. <b>2020</b> , 38, 162-170		7
1049	Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group. <b>2020</b> , 104, 361-375		7
1048	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1171-1178	4-7	4
1047	Overview and Challenges of Bronchiolar Disorders. <b>2020</b> , 17, 253-263		2
1046	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 502-508	4-7	5
1045	Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study. <b>2020</b> , 83, 1654-1658		1
1044	The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 67, e28079		9
1043	A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 162-170	4-7	3
1042	Graft-versus-Host Disease-Free Relapse-Free Survival Definition for Patients with Nonmalignant Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 428	4-7	0
1041	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. <b>2020</b> , 20, 377-382		5



1040	Quantitative Analysis of Thymus-Independent Donor-Derived T Cell Expansion in Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 242-253	4-7	3
1039	Hematopoietic Stem Cell Transplantation. <b>2020</b> , 461-469.e3		1
1038	High incidence of <i>Pneumocystis jirovecii</i> pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. <b>2020</b> , 22, 27-34		9
1037	Chronic Graft Versus Host Myopathies: Noninflammatory, Multi-Tissue Pathology With Glycosylation Disorders. <b>2020</b> , 79, 102-112		4
1036	Dexamethasone palmitate is a feasible option for the treatment of chronic graft-vs-host disease, particularly with macrophage hyperactivation. <b>2020</b> , 24, e13627		1
1035	Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease. <b>2020</b> , 104, e23-e30		10
1034	Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate. <b>2020</b> , 28, 3679-3689		5
1033	Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. <b>2020</b> , 61, 869-874		10
1032	Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 943-948	4-7	5
1031	Risk Factors for Acute Kidney Injury and Chronic Kidney Disease following Allogeneic Hematopoietic Stem Cell Transplantation for Hematopoietic Malignancies. <b>2020</b> , 143, 452-464		4
1030	Best Practices of Apheresis in Hematopoietic Cell Transplantation. <b>2020</b> ,		
1029	Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT. <b>2020</b> , 147, 1071-1077		4
1028	[Intestinal microbiota and allogeneic stem cell transplantation]. <b>2020</b> , 107, 72-83		2
1027	European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. <b>2020</b> , 34, 2693-2716		18
1026	Is It Better to Mobilize Hematopoietic Stem Cells With Pegfilgrastim in Healthy Donors During Allogeneic Hematopoietic Stem Cell Transplantation?. <b>2020</b> , 10, 1598		1
1025	[Cutaneous manifestations of graft versus host disease in a population of pediatric and young adults patients]. <b>2020</b> , 118, e468-e475		
1024	Efficacy and safety of high-dose budesonide/formoterol in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant. <b>2020</b> , 12, 4183-4195		0
1023	[Hematopoietic stem cell transplantation ocular complications: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. <b>2020</b> , 107, S116-S121		1

1022	Secondary Causes of Myositis. <b>2020</b> , 22, 38		2
1021	Early Arterial Intimal Thickening and Plaque Is Related with Treatment Regime and Cardiovascular Disease Risk Factors in Young Adults Following Childhood Hematopoietic Stem Cell Transplantation. <b>2020</b> , 9,		3
1020	Histopathological Grading of Oral Mucosal Chronic Graft-versus-Host Disease: Large Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1971-1979	4-7	1
1019	Male Sexual Function after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Multicenter Study. <b>2020</b> , 12,		1
1018	Long-term Follow-up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics. <b>2020</b> , 40, 808-841		2
1017	Create a healthy diet after transplant!. <b>2020</b> , 136, 8-9		8
1016	Fludarabine, Campath, and Low-Dose Cyclophosphamide (FCC) with or without TBI Conditioning Results in Excellent Transplant Outcomes in Children with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1900-1905	4-7	1
1015	Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2053-2060	4-7	14
1014	Extracorporeal Photopheresis in Graft-versus-Host Disease. <b>2020</b> , 47, 214-225		13
1013	Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. <b>2020</b> , 1, 286-292		8
1012	How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft--Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. <b>2020</b> , 11, 583564		2
1011	Kinetics and clinical significance of human herpesvirus 6 DNA shedding in saliva after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 23, e13512		1
1010	Immune Status Against Hepatitis B in Patients After Allogeneic Hematopoietic Cell Transplantation-Factors Affecting Early and Long-Lasting Maintenance of Protective Anti-HBs Titers. <b>2020</b> , 11, 586523		1
1009	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <b>2020</b> , 172, 229-239		48
1008	Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. <b>2020</b> , 4, 4474-4482		9
1007	Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. <b>2020</b> , 112, 674-689		5
1006	Prevalence of Persistent Corneal Epithelial Defects in Chronic Ocular Graft-Versus-Host Disease. <b>2020</b> , 218, 296-303		6
1005	Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation. <b>2020</b> , 67, e28568		3

1004	Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. <b>2020</b> , 21, 1201-1212		75
1003	The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. <b>2020</b> , 24, e13793		
1002	Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2020</b> , 11, 1505		2
1001	Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant? (Running Title: The Role of Salvage alloSCT in MM). <b>2020</b> , 9,		1
1000	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <b>2020</b> , 9,		
999	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <b>2020</b> , 61, 1823-1832		1
998	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1655-1662	4-7	2
997	Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2115-2120	4-7	3
996	Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2020</b> , 10, 1043-1061		2
995	Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. <b>2020</b> , 12,		40
994	Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. <b>2020</b> , 4, 3669-3676		0
993	Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study. <b>2020</b> , 29, 963689720949175		1
992	Challenging and Practical Aspects of Nutrition in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, e265-e270	4-7	1
991	Chronic Oral Lesions. <b>2020</b> , 38, 451-466		1
990	Impact of Clostridioides difficile infection on the outcome of patients receiving a hematopoietic stem cell transplantation. <b>2020</b> , 99, 428-436		2
989	Topical sirolimus for management of refractory oral chronic graft-versus-host disease. <b>2021</b> , 27, 1451-1454		0
988	The Roles of T Cells in Hematopoietic Stem Cell Transplantation. <b>2020</b> , 29, 963689720966980		1
987	Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation. <b>2020</b> , 11, 575492		5

986	Prognostic Factors for Postrelapse Survival after ex Vivo CD34-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2040-2046	4-7	1
985	Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience. <b>2020</b> , 22, 445-449		4
984	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1876-1885	4-7	1
983	Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. <b>2020</b> , 20, 813-819.e1		3
982	Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review. <b>2020</b> , 13, 1119-1130		1
981	Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation. <b>2020</b> , 99, 2529-2538		7
980	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <b>2020</b> , 4, 2409-2417		6
979	Risk factors for secondary poor graft function after bone marrow transplantation in children with acquired aplastic anemia. <b>2020</b> , 24, e13828		2
978	Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. <b>2020</b> , 4, 4430-4437		7
977	Steroid-refractory acute graft-versus-host disease graded III-IV in pediatric patients. A mono-institutional experience with a long-term follow-up. <b>2020</b> , 24, e13806		1
976	Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation. <b>2020</b> , 26, 6483-6493		3
975	Exosome: From leukemia progression to a novel therapeutic approach in leukemia treatment. <b>2020</b> , 46, 698-715		3
974	Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. <b>2020</b> , 99, 2181-2190		3
973	Case 281: Thoracic Air Leak Syndrome in a Patient with Hematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. <b>2020</b> , 296, 710-714		0
972	Quantitative Lung Imaging in Hematopoietic Cell Transplant Recipients: A Window Into the Physiology of Bronchiolitis Obliterans. <b>2020</b> , 158, 852-853		
971	Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation. <b>2020</b> , 61, 3137-3145		6
970	Diagnostic disagreement between clinical standard histopathological- and retrospective assessment of histopathology-based gastrointestinal graft-versus-host disease in children. <b>2020</b> , 24, e13824		1
969	IL- $\gamma$ Aggravates Murine Chronic Graft--Host Disease by Enhancing T and B Cell Responses. <b>2020</b> , 11, 559740		1

968	Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease. <b>2020</b> , 11, 602547		4
967	Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. <b>2020</b> , 12,		3
966	Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Italiano Trapianto di Midollo Osseo. <b>2020</b> , 79-80, 110998		0
965	Machine Learning Algorithms to Differentiate Among Pulmonary Complications After Hematopoietic Cell Transplant. <b>2020</b> , 158, 1090-1103		5
964	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <b>2020</b> , 38, 2062-2076		19
963	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 55, 2087-2097		3
962	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <b>2020</b> , 55, 2147-2159		11
961	Oral health in allogeneic hematopoietic stem cells transplantation survivors. <b>2020</b> , 55, 2211-2214		1
960	Clinical Usefulness of Bronchoalveolar Lavage in the Management of Pulmonary Infiltrates in Adults with Hematological Malignancies and Stem Cell Transplantation. <b>2020</b> , 12, e2020025		0
959	Long-term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <b>2020</b> , 55, 1725-1735		9
958	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <b>2020</b> , 99, 1377-1387		3
957	Association between P2X7 Polymorphisms and Post-Transplant Outcomes in Allogeneic Haematopoietic Stem Cell Transplantation. <b>2020</b> , 21,		4
956	CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1469-1476	4.7	6
955	Multidimensional geriatric assessment for elderly hematological patients (≥80 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <b>2020</b> , 55, 2224-2233 <sup>11</sup>		11
954	Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. <b>2020</b> , 135, 1739-1749		94
953	Preservation of fertility in patients with hematological malignancies. <b>2020</b> , 50, 729-742		2
952	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study. <b>2020</b> , 33, 1089-1098		
951	Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1729-1737	4.7	4

950	Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. <b>2020</b> , 4, 2227-2235	15
949	Hematopoietic cell transplantation for Diamond Blackfan anemia: A report from the Pediatric Group of the Brazilian Bone Marrow Transplantation Society. <b>2020</b> , 105, 426-433	1
948	T Cell Clonal Dynamics Determined by High-Resolution TCR- $\beta$ Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1567-1574	4-7 6
947	Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <b>2020</b> , 104, 1070-1080	3
946	Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach. <b>2020</b> , 11, 141-162	5
945	Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies. <b>2020</b> , 99, 1883-1893	5
944	Health-related quality of life in patients with bronchiolitis obliterans. <b>2020</b> , 55, 2361-2367	1
943	Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. <b>2020</b> , 4, 1760-1769	7
942	Outcomes of allogeneic haematopoietic stem cell transplantation for patients with severe aplastic anaemia using the porcine antilymphocyte globulin-containing conditioning regimen. <b>2020</b> , 99, 1863-1871	1
941	Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease. <b>2020</b> , 146, 2967-2978	2
940	T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies. <b>2020</b> , 8, 282	11
939	Acute Graft-versus-Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment. <b>2020</b> , 40, 788-807	1
938	Histological and magnified endoscopic evaluation of villous atrophy in gastrointestinal graft-versus-host disease. <b>2020</b> , 99, 1121-1128	1
937	Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients. <b>2020</b> , 25, 125-133	1
936	Ruxolitinib for the treatment of graft-versus-host disease. <b>2020</b> , 16, 347-359	5
935	Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies. <b>2020</b> , 69, 683-687	9
934	Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children. <b>2020</b> , 83, 106371	2
933	Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. <b>2020</b> , 190, 84-92	7

932	Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency. <b>2020</b> , 31, 515-527		7
931	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1288-1297	4.7	7
930	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1679-1688	4.7	8
929	Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1803-1810	4.7	3
928	Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers. <b>2020</b> , 11, 1338		25
927	Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1906-1914	4.7	1
926	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1868-1875	4.7	4
925	Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin. <b>2020</b> , 34, e14018		2
924	Noninfectious pulmonary complications of haematopoietic stem cell transplantation. <b>2020</b> , 29,		13
923	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 95, 1170		1
922	Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. <b>2020</b> , 38, 597-603		4
921	Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1875-1880	4.7	6
920	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <b>2020</b> , 38, 1518-1526		16
919	Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, e113-e127	4.7	8
918	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, e94-e100	4.7	2
917	Permanent Impairment-Free, Relapse-Free Survival: A Novel Composite Endpoint to Evaluate Long-Term Success in Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1005-1012	4.7	0
916	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1084-1090	4.7	11
915	Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <b>2020</b> , 20, 2198-2205		8

914	Reconstitution of Circulating Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation: Its Association with the Riboflavin Synthetic Pathway of Gut Microbiota in Cord Blood Transplant Recipients. <b>2020</b> , 204, 1462-1473		22
913	Total Marrow Irradiation. <b>2020</b> ,		1
912	Two decades of experience in a combined adult/pediatric allogeneic hematopoietic stem cell transplantation center in Algiers, Algeria. <b>2020</b> , 99, 619-625		1
911	HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation. <b>2020</b> , 55, 1658-1661		1
910	Quality of Life in Patients With Skin of Color and Chronic Graft-vs-Host Disease. <b>2020</b> , 156, 589-590		
909	Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report. <b>2020</b> , 2020, 5852827		12
908	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <b>2020</b> , 7, e157-e167		116
907	Diagnostic and Prognostic Biomarkers for Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2020</b> , 47, E35-E43		
906	The role of serum uric acid in the prediction of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 34, e23271		14
905	Long-Term Immunity to Measles after Allogeneic Hematopoietic Cell Transplantation: Factors Associated with Seroprotection before Revaccination. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 985-991	4-7	1
904	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. <b>2020</b> , 22, 158-165		8
903	Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease(GVHD). <b>2020</b> , 18, 298-304		12
902	Effects and long-term follow-up of using umbilical cord blood-derived mesenchymal stromal cells in pediatric patients with severe BK virus-associated late-onset hemorrhagic cystitis after unrelated cord blood transplantation. <b>2020</b> , 24, e13618		4
901	Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation in children. <b>2020</b> , 55, 631-637		4
900	Prospective validation of the L-index reflecting both the intensity and duration of lymphopenia and its detailed evaluation using a lymphocyte subset analysis after allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 58, 101262		2
899	Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 956-964	4-7	6
898	Chronic Graft-Versus-Host-Disease-Related Polymyositis: a 17-Months-Old Child with a Rare and Late Complication of Haematopoietic Stem Cell Transplantation. <b>2020</b> , 12, e2020002		4
897	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 893-901	4-7	7



896	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1179-1188	4-7	14
895	Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation. <b>2020</b> , 99, 839-845		6
894	The management of gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation-a single-center real-life experience. <b>2020</b> , 99, 1361-1368		1
893	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). <b>2020</b> , 55, 1906-1917		17
892	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <b>2020</b> , 11, 586		3
891	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. <b>2020</b> , 95, 809-816		14
890	Ocular Graft-Versus-Host Disease Topic Review. <b>2020</b> , 8, 36-43		2
889	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1332-1341	4-7	17
888	Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. <b>2020</b> , 13, 519-532		9
887	The predictive value of serum free light chain level early after allogeneic hematopoietic stem cell transplantation for chronic graft-versus-host disease, a preliminary study. <b>2020</b> , 34, e13865		
886	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. <b>2020</b> , 22, e13289		6
885	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. <b>2020</b> , 4, 1656-1669		40
884	Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment. <b>2020</b> , 34, e791-e793		0
883	The challenge of long-term follow-up of survivors of childhood acute leukemia after hematopoietic stem cell transplantation in resource-limited countries: A single-center report from Brazil. <b>2020</b> , 24, e13691		1
882	Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial. <b>2020</b> , 9, 5		2
881	Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. <b>2020</b> , 95, 927-936		16
880	Clinical relevance of endoscopy with histopathological assessment in children with suspected gastrointestinal graft-versus-host disease. <b>2020</b> , 34, e13867		3
879	A few steps on the long road toward biomarkers in GVHD. <b>2020</b> , 135, 1196-1197		1

878	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <b>2020</b> , 4, 40-46	3
877	Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. <b>2020</b> , 105, 2639-2646	5
876	Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications. <b>2020</b> , 11, 422	12
875	Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. <b>2020</b> , 61, 1996-2002	6
874	A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis. <b>2021</b> , 144, 158-165	10
873	Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study. <b>2021</b> , 56, 70-83	1
872	Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study. <b>2021</b> , 15, 108-115	1
871	Allogeneic Bone Marrow Mesenchymal Stromal Cell Therapy in Patients with Steroid-Refractory Graft Versus Host Disease: Pilot Study from Pakistan. <b>2021</b> , 7, 234-243	
870	Oral Graft-Versus-Host Disease: A Pictorial Review and a Guide for Dental Practitioners. <b>2021</b> , 71, 9-20	6
869	Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children : Results of a prospective study on behalf of the German-Austrian-Swiss GVHD Consortium. <b>2021</b> , 133, 41-51	1
868	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. <b>2021</b> , 56, 38-49	2
867	Allogeneic hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt from a tertiary care center in India. <b>2021</b> , 25, e13918	1
866	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. <b>2021</b> , 100, 541-553	4
865	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. <b>2021</b> , 100, 169-180	7
864	Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 56, 293-296	4
863	Chronic ocular graft-versus-host disease after allogeneic haematopoietic stem cell transplantation in Denmark - factors associated with risks and rates in adults according to conditioning regimen. <b>2021</b> , 56, 144-154	3
862	Extracorporeal Photochemotherapy (Photopheresis). <b>2021</b> , 271-279.e4	
861	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <b>2021</b> , 56, 137-143	5

860	Prevalence of untreated and uncontrolled cardiovascular risk factors in survivors of allogeneic cell transplantation. <b>2021</b> , 56, 167-174	3
859	Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. <b>2021</b> , 56, 745-748	2
858	Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia. <b>2021</b> , 56, 586-595	8
857	Analysis of serum and salivary cytokines among patients with oral cGVHD after Allo-HSCT. <b>2021</b> , 27, 1320-1324	1
856	Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. <b>2021</b> , 35, 1563-1570	16
855	Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. <b>2021</b> , 18, 381-394	8
854	Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 106, 114-125	1
853	Concurrent Reductions in Spirometry Predict Mortality and Bronchiolitis Obliterans in Chronic Graft-versus-Host Disease. <b>2021</b> , 18, 720-723	1
852	Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. <b>2021</b> , 106, 606-615	1
851	Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. <b>2021</b> , 22, 169-180	1
850	Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes. <b>2021</b> , 41, 414-426	4
849	Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease. <b>2021</b> , 56, 909-916	10
848	Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. <b>2021</b> , 100, 959-968	9
847	Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. <b>2021</b> , 106, 205-212	
846	Pulmonary Manifestations of Immunodeficiency and Immunosuppressive Diseases Other than Human Immunodeficiency Virus. <b>2021</b> , 68, 103-130	0
845	Immune Reconstitution Following TCR $\alpha$ CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients. <b>2021</b> , 27, 169.e1-169.e9	4
844	Impact of Allogeneic Stem Cell Transplantation on Testicular and Sexual Function. <b>2021</b> , 27, 182.e1-182.e8	0
843	Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children. <b>2021</b> , 106, 408-416	0

842	Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. <b>2021</b> , 25, 1089-1099	9
841	Efficacy of low dose antithymocyte globulin on overall survival, relapse rate, and infectious complications following allogeneic peripheral blood stem cell transplantation for leukemia in children. <b>2021</b> , 56, 890-899	3
840	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. <b>2021</b> , 56, 883-889	2
839	Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. <b>2021</b> , 100, 1579-1591	3
838	Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 100, 517-527	1
837	Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients. <b>2021</b> , 113, 145-157	
836	Sexual Functioning in Long-Term Survivors of Hematopoietic Cell Transplantation. <b>2021</b> , 27, 80.e1-80.e12	4
835	Determinants of cardiorespiratory fitness in very long-term survivors of allogeneic hematopoietic stem cell transplantation: a national cohort study. <b>2021</b> , 29, 1959-1967	1
834	Altered body composition in male long-term survivors of paediatric allogeneic haematopoietic stem cell transplantation: impact of conditioning regimen, chronic graft-versus-host disease and hypogonadism. <b>2021</b> , 56, 457-460	4
833	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 223, 1564-1575	7
832	Chronic graft-versus-host disease in pancreas after kidney transplant recipients - An unrecognized entity. <b>2021</b> , 21, 883-888	1
831	Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. <b>2021</b> , 56, 243-256	3
830	Chronic Graft-Versus-Host Disease. <b>2021</b> , 453-476	
829	Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. <b>2021</b> , 26, 186-198	0
828	Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts. <b>2021</b> , 26, 134-143	1
827	Rashes to Recognize in the Immunocompromised Transplant Patient: Focus on the Solid Organ Transplant Recipient. <b>2021</b> , 1577-1594	
826	Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. <b>2021</b> , 23, e13544	2
825	Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant. <b>2021</b> , 10, e1249	8

824	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <b>2021</b> , 100, 505-516	2
823	Comments on: Ocular surface characterization after allogeneic stem cell transplantation: A prospective study in a referral center. <b>2021</b> , 69, 459-460	
822	Gastrointestinal Pathology. <b>2021</b> , 696-716.e7	
821	Study of clinical characteristics, risk factors and outcomes for tuberculosis post allogeneic stem cell transplant: never count it out. <b>2021</b> , 8, 20499361211008674	
820	Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience. <b>2021</b> , 56, 1455-1457	1
819	BK Virus Epidemiology, Risk Factors, and Clinical Outcomes: An Analysis of Hematopoietic Stem Cell Transplant Patients at Texas Children's Hospital. <b>2021</b> , 10, 492-501	0
818	The Association between Meibomian Gland Atrophy and Corneal Subbasal Nerve Loss in Patients with Chronic Ocular Graft-versus-host Disease. <b>2021</b> , 46, 796-801	2
817	Platelet lysate: a promising candidate in regenerative medicine. <b>2021</b> , 16, 71-85	4
816	Biology of Graft-Versus-Host Disease. <b>2021</b> , 55-73	
815	Acute Graft-Versus-Host Disease (GvHD). <b>2021</b> , 423-452	
814	Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant. <b>2021</b> , 10, 35-39	
813	Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms. <b>2021</b> , 35, 2379-2390	
812	Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?. <b>2021</b> , 12, 20406207211001135	
811	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. <b>2021</b> , 137, 126-137	14
810	"Is this the GVHD?" A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service. <b>2021</b> , 19, 11	3
809	Radiology Pearls for the Transplant Provider. <b>2021</b> , 401-422	
808	Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLL3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival. <b>2021</b> , 100, 1303-1309	0
807	Extracorporeal Photopheresis in Pediatric Graft-vs-Host Disease. <b>2021</b> , 112, 625-625	

806	Face transplantation: A longitudinal histological study focusing on chronic active and mucosal rejection in a series with long-term follow-up. <b>2021</b> , 21, 3088-3100	0
805	Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome. <b>2021</b> , 56, 1635-1641	0
804	Association Between Baseline Patient-Reported Outcomes and Complications of Hematopoietic Stem Cell Transplantation. <b>2021</b> , 27, 496.e1-496.e5	0
803	Updated prevalence, predictors and treatment outcomes for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. <b>2020</b> , 177, 106286	2
802	Dental biofilm microbiota dysbiosis is associated with the risk of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.	2
801	The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study. <b>2021</b> , 15, 743-752	4
800	Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease. <b>2020</b> , 11, 574569	3
799	Functional Contributions of Antigen Presenting Cells in Chronic Graft-Versus-Host Disease. <b>2021</b> , 12, 614183	1
798	Association of graft-versus-host-disease with neurologic complications: clinical paradigm and future directions. <b>2021</b> , 56, 1471-1473	
797	Elafin as a Predictive Biomarker of Acute Skin Graft--Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide. <b>2021</b> , 12, 516078	3
796	Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation. <b>2020</b> , 11, 614488	1
795	Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation. <b>2021</b> , 11, 3230	0
794	Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis. <b>2021</b> , 100, 969-978	
793	Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis. <b>2021</b> , 93, 6292-6300	1
792	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. <b>2021</b> , 5, 1154-1163	5
791	Gastrointestinal complications. <b>2021</b> , 260-270	
790	Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases. <b>2021</b> , 114, 116-123	1
789	Immune-mediated neuromuscular complications of graft-versus-host disease. <b>2021</b> , 63, 852-860	2

788	Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. <b>2021</b> , 8, e229-e239	2
787	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <b>2021</b> , 35, 2672-2683	15
786	Skin chronic GVHD. <b>2021</b> , 140-165	
785	Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial. <b>2021</b> , 5, 1250-1258	2
784	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <b>2021</b> , 100, 1311-1319	
783	Posttransplant Considerations in Gender, Reproductive, and Sexual Health. <b>2021</b> , 198-210	
782	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. <b>2021</b> , 27, 492.e1-492.e6	2
781	Hepatic Complications. <b>2021</b> , 271-277	
780	Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. <b>2021</b> , 27, 493.e1-493.e8	1
779	Ocular complications. <b>2021</b> , 166-175	
778	Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. <b>2021</b> , 5, 1199-1208	11
777	Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. <b>2021</b> , 12, 640082	18
776	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. <b>2021</b> , 100, 1743-1753	2
775	Wnt/βcatenin signaling mediates the abnormal osteogenic and adipogenic capabilities of bone marrow mesenchymal stem cells from chronic graft-versus-host disease patients. <b>2021</b> , 12, 308	0
774	Late non-infectious pulmonary complications. <b>2021</b> , 231-240	
773	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. <b>2021</b> , 27, 253.e1-253.e9	0
772	Tear Lipid Metabolites As Potential Diagnostic Biomarkers for Ocular Chronic Graft-Versus-Host Disease. <b>2021</b> , 27, 232.e1-232.e6	1
771	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <b>2021</b> , 2, 236-248	1

770	Ruxolitinib for the treatment of chronic GVHD and overlap syndrome in children and young adults. <b>2021,</b>	5
769	Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study. <b>2021, 8, 630160</b>	2
768	Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study. <b>2021, 56, 1850-1858</b>	1
767	High proportion of terminally differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. <b>2021, 56, 1828-1841</b>	0
766	Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months. <b>2021, 34, 101253</b>	1
765	Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. <b>2021, 27, 271.e1-271.e8</b>	2
764	Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy. <b>2021, 27, 246-252</b>	2
763	The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation. <b>2021, 61, 1505-1517</b>	1
762	Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity. <b>2021, 38, 331-345</b>	6
761	Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation. <b>2021, 12, 651751</b>	2
760	Management of oral and dental complications. <b>2021, 176-182</b>	
759	Late effects post-allogeneic hematopoietic stem cell transplantation. <b>2021, 38-46</b>	
758	Nutritional support and nutritional supplementation. <b>2021, 393-396</b>	
757	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. <b>2021, 27, 2712-2722</b>	5
756	Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. <b>2021, 96, 671-679</b>	13
755	Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation. <b>2021, 113, 1405-1414</b>	1
754	The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury. <b>2021, 137, 1679-16896</b>	
753	Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease. <b>2021, 23, 30</b>	4



752	Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <b>2021</b> , 56, 2160-2172	2
751	Oral health-related quality of life of patients with oral chronic graft-versus-host disease. <b>2021</b> , 29, 6353-6360	2
750	Gynecologic Care for Pediatric and Adolescent Patients Undergoing Hematopoietic Stem Cell Transplantation. <b>2021</b> , 34, 112-116	0
749	Obliterans With Organizing Pneumonia: A Possible Misdiagnosis of Lung Graft-Versus-Host Disease in Posttransplant Patients With COVID-19. <b>2021</b> , 19, 393-395	
748	Long-term outcome after allogeneic stem cell transplantation in multiple myeloma. <b>2021</b> , 100, 1553-1567	5
747	Rehabilitation Interventions in the Multidisciplinary Management of Patients With Sclerotic Graft-Versus-Host Disease of the Skin and Fascia. <b>2021</b> , 102, 776-788	1
746	Positive Effects of Oral Antibiotic Administration in Murine Chronic Graft-Versus-Host Disease. <b>2021</b> , 22,	1
745	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. <b>2021</b> , 56, 2097-2107	2
744	Current Concepts and Advances in Graft-Versus-Host Disease Immunology. <b>2021</b> , 39, 19-49	20
743	Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. <b>2021</b> , 10, 2956-2966	1
742	Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience. <b>2021</b> , 12, 621935	0
741	Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide. <b>2021</b> , 11, 666774	0
740	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 11, 8527	2
739	Two case reports of continued progression of chronic ocular graft-versus-host disease without concurrent systemic comorbidities treated by amniotic membrane transplantation. <b>2021</b> , 21, 164	1
738	B regulatory cells and monocyte subpopulations in patients with chronic graft-vs-host disease. <b>2021</b> , 62, 154-164	0
737	Allogeneic hematopoietic stem cell transplantation in children with lymphoblastic lymphoma. <b>2021</b> , 20, 91-98	
736	Successful rescue transplant for children with primary graft failure using early intervention with a single day preparative regimen and related haploidentical donor. <b>2021</b> , 56, 2031-2033	0
735	MSCs Become Collagen-Type I Producing Cells with Different Phenotype in Allogeneic and Syngeneic Bone Marrow Transplantation. <b>2021</b> , 22,	

734	Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. <b>2021</b> , 12, 605766	6
733	Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review. <b>2021</b> , 13,	1
732	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. <b>2021</b> , 56, 2445-2453	1
731	Head-to-head Comparison of Qualitative Radiologist Assessment With Automated Quantitative Computed Tomography Analysis for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation. <b>2021</b> ,	1
730	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <b>2021</b> , 27, 428.e1-428.e9	1
729	Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant. <b>2021</b> , 12, 674658	1
728	Extracorporeal Photopheresis in Pediatric Graft-vs-Host Disease. <b>2021</b> ,	
727	What Do the Lips Say in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation? A Case Series. <b>2021</b> , 11, 1423-1434	0
726	Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia. <b>2021</b> , 27, 424.e1-424.e9	6
725	Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience. <b>2021</b> , 100, 1837-1847	1
724	Selection Criteria for Lung Transplantation: Controversies and New Developments. <b>2021</b> , 42, 329-345	
723	Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 23, e13626	1
722	Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. <b>2021</b> , 10, 3165-3176	1
721	Sexuality- and Fertility-Related Issues in Women after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 27, 432.e1-432.e6	1
720	CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation. <b>2021</b> , 135,	0
719	Long-term Outcomes of Cataract Surgery in Patients With Chronic Ocular Graft-Versus-Host Disease. <b>2021</b> ,	0
718	Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. <b>2021</b> , 27, 433.e1-433.e8	1
717	International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. <b>2021</b> ,	9

716	Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with High-Risk Leukemia Using a Reduced-Intensity Conditioning Regimen and Peripheral Blood as the Stem Cell Source. <b>2021</b> , 27, 427.e1-427.e7	3
715	Thoracic Air Leak Syndrome, Pulmonary Aspergillosis, and COVID-19 Pneumonia After Allogeneic Stem Cell Transplantation in a Child With Myelodysplastic Syndrome. <b>2021</b> ,	1
714	Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation. <b>2021</b> , 56, 2423-2431	5
713	Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia. <b>2021</b> , 13,	1
712	A bi-centric experience of extracorporeal carbon dioxide removal (ECCO R) for acute hypercapnic respiratory failure following allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 45, 903-910	2
711	Connective Tissue Growth Factor Is Overexpressed in Explant Lung Tissue and Broncho-Alveolar Lavage in Transplant-Related Pulmonary Fibrosis. <b>2021</b> , 12, 661761	4
710	Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. <b>2021</b> , 27, 920.e1-920.e9	
709	Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. <b>2021</b> , 56, 2410-2422	1
708	Comparison of non-first-degree related donors and first-degree related donors in haploidentical HSCT: a multi-centre retrospective analysis. <b>2021</b> , 56, 2567-2574	1
707	The significance of focally enhanced gastritis in haematopoietic stem cell transplant recipients. <b>2021</b> , 79, 599-606	
706	Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells. <b>2021</b> , 5, 424-437	2
705	Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. <b>2021</b> , 12, 673636	1
704	Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas. <b>2021</b> , 56, 2295-2298	
703	Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT. <b>2021</b> , 56, 2651-2655	0
702	Prophylactic pretransplant ganciclovir to reduce cytomegalovirus infection after hematopoietic stem cell transplantation. <b>2021</b> ,	0
701	Conjunctival Matrix Metalloproteinase-9 Clinical Assessment in Early Ocular Graft versus Host Disease. <b>2021</b> , 2021, 9958713	1
700	Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 12, 668825	2
699	Autoantibodies against the plaklin family proteins as a novel marker for chronic graft-versus-host disease of the lung. <b>2021</b> , 56, 2291-2294	

698	Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children. <b>2021</b> , 1	0
697	Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. <b>2021</b> , 131,	2
696	Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease. <b>2021</b> , 98, 36-46.e2	2
695	ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. <b>2021</b> , 39, 1888-1898	33
694	Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation. <b>2021</b> , 107, 393-407	3
693	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. <b>2021</b> , 3, 250-259	6
692	Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease. <b>2021</b> , 22,	1
691	Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. <b>2021</b> , 12, 705342	0
690	Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 12, 692225	1
689	Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?. <b>2021</b> , 56, 2489-2496	2
688	Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 53, 2013-2020	
687	Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. <b>2021</b> , 27, 616.e1-616.e6	5
686	NELL1-Associated Membranous Glomerulopathy After Hematopoietic Stem Cell Transplantation. <b>2021</b> , 6, 1992-1995	1
685	Clinical characteristics and viral load patterns in children with cytomegalovirus gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 56, 2813-2819	1
684	Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. <b>2021</b> , 56, 2079-2087	8
683	FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases. <b>2021</b> , 27, 915.e1-915.e8	08
682	Lung hyperinflation quantitated by chest CT in children with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell transplantation. <b>2021</b> , 75, 97-104	0
681	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <b>2021</b> , 385, 228-238	48

680	Pulmonary Complications in Hematopoietic Stem Cell Transplant Recipients-A Clinician Primer. <b>2021</b> , 10,	2
679	Significant Associations of IgG Glycan Structures With Chronic Graft-Versus-Host Disease Manifestations: Results of the Cross-Sectional NIH Cohort Study. <b>2021</b> , 12, 633214	
678	Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation - A single center retrospective efficacy analysis. <b>2021</b> , 39, 4742-4750	1
677	A Review of Ocular Graft-versus-Host Disease: Pathophysiology, Clinical Presentation and Management. <b>2021</b> , 1-10	4
676	Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 27, 949.e1-949.e8	
675	Acute pancreatitis following allogeneic hematopoietic stem cell transplantation in children. <b>2021</b> , 114, 494-501	0
674	Oral white lesion in patients post-hematopoietic stem cell transplantation: a case series demonstrating the diagnostic dilemma. <b>2021</b> , 29, 7999-8007	1
673	Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation. <b>2021</b> , 227, 25-34	8
672	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. <b>2021</b> , 11, 705568	0
671	Successful haploidentical transplantation using plasma exchange and post-transplantation cyclophosphamide for severe aplastic anemia patients with anti-human leukocyte antigen donor-specific antibodies. <b>2021</b> , 100, 2381-2385	0
670	Haploidentical haematopoietic stem cell transplantation for malignant infantile osteopetrosis and intermediate osteopetrosis: a retrospective analysis of a single centre. <b>2021</b> , 16, 314	0
669	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. <b>2021</b> , 56, 2723-2731	0
668	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <b>2021</b> , 27, 545-557	15
667	A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. <b>2021</b> , 9, 634449	1
666	Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease. <b>2021</b> , 27, 925.e1-925.e7	1
665	Haploidentical haematopoietic stem cell transplantation for the treatment of severe aplastic anaemia patients with high-risk factors who lack an HLA-matched sibling donor. <b>2021</b> ,	
664	Hematopoietic Dysfunction during Graft-Versus-Host Disease: A Self-Destructive Process?. <b>2021</b> , 10,	1
663	Extracorporeal Photopheresis in Children with Chronic Graft-Versus-Host Disease. <b>2021</b> , 14,	

662	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. <b>2021</b> , 56, 2964-2974	0
661	Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial. <b>2021</b> , 56, 2948-2955	0
660	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <b>2021</b> , 27, 679.e1-679.e8	0
659	Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. <b>2021</b> , 27, 926.e1-926.e10	0
658	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <b>2021</b> , 27, 917.e1-917.e9	0
657	Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors. <b>2021</b> , 114, 674-681	0
656	Major pulmonary complications following Hematopoietic stem cell transplantation: What the pulmonologist needs to know. <b>2021</b> , 185, 106493	1
655	The Pathophysiology and Treatment of Graft–Host Disease: Lessons Learnt From Animal Models. <b>2021</b> , 12, 715424	3
654	Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. <b>2021</b> , 27, 667.e1-667.e5	0
653	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <b>2021</b> , 107, 573-582	1
652	Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study. <b>2021</b> , 96, 1429-1440	0
651	Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. <b>2021</b> , 96, 1441-1449	0
650	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. <b>2021</b> , 27, 668.e1-668.e9	0
649	Antibiotic administration exacerbates acute graft vs. host disease-induced bone marrow and spleen damage in lymphopenic mice. <b>2021</b> , 16, e0254845	0
648	Usefulness of high-frequency ultrasonography in the evaluation and monitoring of sclerosing dermatoses: a cohort study. <b>2021</b> ,	1
647	The association of lung function changes with outcomes in children with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <b>2021</b> , 56, 3332-3341	1
646	Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. <b>2021</b> , 27, 909.e1-909.e6	0
645	Late Post-Operative Occurrence of Dentin Hypersensitivity in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation-A Preliminary Report. <b>2021</b> , 18,	

644	Observation of Chronic Graft-Versus-Host Disease Mouse Model Cornea with In Vivo Confocal Microscopy. <b>2021</b> , 11,	0
643	Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease. <b>2021</b> , 56, 2934-2939	1
642	Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 5, 4910-4921	0
641	Oral manifestations of graft-versus-host disease in patients submitted to allogeneic hematopoietic stem cell transplantation: the experience of a Brazilian Cancer Center. <b>2022</b> , 30, 567-573	
640	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. <b>2021</b> , 96, 1407-1419	0
639	Janus Kinase Inhibitors and Cell Therapy. <b>2021</b> , 12, 740847	2
638	Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible in Pediatric Patients with an Active or Recently Diagnosed Invasive Fungal Infection. <b>2021</b> , 27, 781.e1-781.e5	0
637	Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell	1
636	Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia. <b>2021</b> , 56, 3042-3048	1
635	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <b>2021</b> , 5, 3387-3396	4
634	Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients. <b>2021</b> , 56, 3032-3041	0
633	Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children. <b>2021</b> , 56, 2981-2989	1
632	Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. <b>2021</b> , 28, 18.e1-18.e1	0
631	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <b>2021</b> , 27, 729-737	5
630	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. <b>2021</b> , 27, 738-746	2
629	[Cutaneous complications following hematopoietic stem cell transplantation]. <b>2021</b> , 108, 877-885	
628	Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology. <b>2021</b> ,	0
627	Oral shedding of herpesviruses and clinical outcomes in hematopoietic stem cell transplant patients. <b>2021</b> ,	

626	Shellfish allergy-induced overlap chronic graft-versus-host disease. <b>2021</b> , 17, 100-102	
625	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <b>2021</b> , 27, 759.e1-759.e8	0
624	Surgically treated genital chronic graft-versus-host disease in women: A report of three cases. <b>2021</b> , 47, 4122-4126	0
623	Early Detection of Vulvovaginal Graft-Versus-Host Disease: An Integrative Review. <b>2021</b> , 12, 725-737	0
622	A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 1	0
621	Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation. <b>2021</b> , 27, 786.e1-786.e8	1
620	Metabolic Syndrome in Male Survivors of Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Total Body Irradiation, Low-Grade Inflammation, and Hypogonadism. <b>2021</b> , 27, 778.e1-778.e8	4
619	Metabolomic Identification of Alpha-Ketoglutaric Acid Elevation in Pediatric Chronic Graft-versus-Host Disease. <b>2021</b> ,	2
618	Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. <b>2021</b> , 56, 2975-2980	0
617	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <b>2021</b> ,	0
616	TCR $\alpha$ CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different non-malignant disorders. <b>2021</b> ,	3
615	Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <b>2021</b> , 27, 760-767	6
614	Longitudinal Tear Protein Changes Correlate with Ocular Chronic GVHD Development in Allogeneic Hematopoietic Stem Cell Transplant Patients. <b>2021</b> , 11, 8221	0
613	Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis. <b>2021</b> , 100, 3007-3016	0
612	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <b>2021</b> , 5, 4278-4284	2
611	Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <b>2021</b> ,	3
610	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <b>2021</b> , 27, 776.e1-776.e13	6
609	Donor bone marrow-derived macrophage MHC II drives neuroinflammation and altered behaviour during chronic GVHD in mice. <b>2021</b> ,	0



608	Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. <b>2021</b> , 5, 4156-4166	0
607	Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease. <b>2021</b> , 27, 777.e1-777.e6	1
606	Keeping an 'eye' on ocular GVHD. <b>2021</b> , 1-8	0
605	Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. <b>2021</b> ,	0
604	Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation. <b>2021</b> , 28, 53.e1-53.e1	1
603	Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. <b>2021</b> , 109, 106642	1
602	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <b>2021</b> , 27, 817-835	5
601	Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. <b>2021</b> , 11,	0
600	Allogeneic Transplant Overview and Matched Related Donor Transplant. <b>2021</b> , 187-221	
599	Graft Versus Host Disease: Management of Acute and Chronic Disease. <b>2021</b> , 365-393	
598	Update on the application of amniotic membrane in immune-related ocular surface diseases. <b>2021</b> , 11, 132-140	1
597	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. <b>2021</b> , 56, 1373-1380	2
596	Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib. <b>2021</b> , 61, 954-960	
595	T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. <b>2021</b> , 5, 240-249	7
594	Long-Term Follow-Up and Chronic Complications. <b>2021</b> , 641-665	
593	Update on ocular graft-versus-host disease. <b>2021</b> , 69, 1038-1050	4
592	Rashes to Recognize in the Immunocompromised Transplant Patient: Focus on the Solid Organ Transplant Recipient. <b>2021</b> , 1-19	
591	Pulmonary Complications. <b>2021</b> , 543-555	

590	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <b>2021</b> , 106, 508-519		
589	Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. <b>2021</b> , 100, 779-787		5
588	Risk Factors for Ocular Involvement in Pediatric Graft-Versus-Host Disease. <b>2021</b> , 40, 1158-1164		0
587	Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA. <b>2021</b> , 11, 253		1
586	Involvement of ocular surface in graft-versus-host disease: An update from immunopathogenesis to treatment. <b>2021</b> , 236, 6190-6199		1
585	Evolving Therapeutic Options for Chronic Graft-versus-Host Disease. <b>2020</b> , 40, 756-772		8
584	Chronic Graft-Versus-Host Disease. <b>2019</b> , 331-345		8
583	Ocular and Oral Complications. <b>2019</b> , 367-371		1
582	Atypical Manifestations of Graft-Versus-Host Disease. <b>2017</b> , 149-160		1
581	Graft-Versus-Host Disease (GvHD). <b>2018</b> , 221-251		4
580	Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation. <b>2020</b> , 625-641		1
579	Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1492-1496	4-7	5
578	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1459-1468	4-7	14
577	Male Gonadal Function after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Cross-Sectional, Population-Based Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1635-1645	4-7	9
576	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1612-1619	4-7	6
575	Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Case Report. <b>2020</b> , 52, 2551-2553		0
574	Increased P2X7 expression in the gastrointestinal tract and skin in a humanised mouse model of graft-versus-host disease. <b>2020</b> , 134, 207-223		11
573	The Overlap Syndrome: A Case Report of Chronic Graft-Versus-Host Disease After the Development of a Pseudomembrane. <b>2021</b> , 40, 1188-1192		1

572	Glycolytic metabolism of pathogenic T cells enables early detection of GvHD by 13C-MRI.	2
571	Identification of oral risk factors for chronic graft versus host disease in haematological patients who underwent allogeneic haematopoietic stem cell transplantation. <b>2017</b> , 10, 390-397	1
570	Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos. <b>2018</b> , 2018,	4
569	C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. <b>2018</b> , 3,	15
568	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <b>2017</b> , 2,	40
567	In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease. <b>2017</b> , 2,	5
566	Cytokine mediators of chronic graft-versus-host disease. <b>2017</b> , 127, 2452-2463	55
565	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. <b>2020</b> , 136, 130-136	45
564	Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD. <b>2019</b> , 3, 1003-1010	19
563	Pulmonary Barotrauma Following Nasal High-Flow Therapy in a Patient with Bronchiolitis Obliterans Syndrome. <b>2019</b> , 20, 1619-1622	2
562	Unexpected Complication of R-CHOP Chemotherapy: Rapidly Progressive Bronchiolitis Obliterans Syndrome. <b>2019</b> , 6, 001266	0
561	Macrophage regulation of graft--host disease. <b>2020</b> , 8, 1793-1805	8
560	Ruxolitinib add-on in corticosteroid-refractory graft--host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. <b>2020</b> , 8, 1065-1073	4
559	Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease. <b>2017</b> , 8, 106333-106341	6
558	Cutaneous manifestations of acute and chronic graft-versus-host disease. <b>2020</b> , 155, 76-87	3
557	Challenges in Conducting Studies in Chronic Graft--Host Disease. <b>2019</b> , 1, 36-44	2
556	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease. <b>2020</b> , 18, eAE4799	1
555	Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD). <b>2020</b> , 11, 81	10

554	[How I treat chronic graft-versus-host disease]. <b>2018</b> , 39, 89-93	1
553	[Alternative donor HSCT for 109 children with acquired severe aplastic anemia: a single center retrospective analysis]. <b>2020</b> , 41, 128-131	2
552	[The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD]. <b>2020</b> , 41, 716-722	1
551	Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). <b>2016</b> , 7, S21-31	28
550	Neurological complications of hematopoietic cell transplantation in children and adults. <b>2018</b> , 13, 945-954	25
549	Follicular Graft-versus-host Disease: A Rare Manifestation in a Patient with the Overlap Subtype of Chronic Graft-versus-host Disease. <b>2019</b> , 64, 324-327	4
548	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <b>2020</b> , 18, 599-634	11
547	Treatment of oral chronic graft-versus-host disease: a retrospective cohort study. <b>2021</b> , 19, eAO6177	
546	Graft Versus Host Disease. <b>2021</b> , 1-23	
545	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. <b>2021</b> , 1	1
544	Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. <b>2021</b> ,	0
543	Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. <b>2021</b> , 12, 761616	5
542	Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. <b>2021</b> ,	4
541	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <b>2021</b> ,	1
540	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <b>2022</b> , 108, 61-72	1
539	Cancers after HLA-matched related bone marrow transplantation for aplastic anemia. <b>2021</b> ,	0
538	Poor survival and prediction of prolonged isolated thrombocytopenia post umbilical cord blood transplantation in patients with hematological malignancies. <b>2021</b> ,	
537	A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity. <b>2021</b> , e14514	1

- 536 Mega-dose 90Y-Ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. **2021**, 0
- 535 Pulmonary Complications After Pediatric Stem Cell Transplant. **2021**, 11, 755878 1
- 534 Phase 2 multicenter trial of ofatumumab and prednisone as initial therapy of chronic graft-vs-host disease. **2021**, 0
- 533 Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease. **2021**, 41, 929-939 0
- 532 The clinical landscape of chronic graft-versus-host disease management in 2021. **2021**, 1
- 531 Graft versus host disease.
- 530 Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. **2015**, 22, 127-135
- 529 Acute and Chronic Graft-Versus-Host Disease of the Skin. **2016**, 101-118
- 528 Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis. **2016**, 9, 279-286 1
- 527 Clinical Immunology in Diagnoses of Maxillofacial Disease. **2017**, 1-25
- 526 Cutaneous Graft-Versus-Host Disease. **2017**, 665-683
- 525 Hematopoietic Stem Cell Transplantation. **2017**,
- 524 HSCT-Associated Complications of the Skin, Hair, and Nails. **2018**, 363-368 0
- 523 Special Care of Blood and Marrow Hematopoietic Cell Transplant Recipient. **2018**, 1211-1245
- 522 Pediatric Graft-Versus-Host Disease. **2018**, 155-169
- 521 Allogene hämatopoetische Stammzelltransplantation. **2018**, 667-674
- 520 Acute Graft Versus Host Disease. **2018**, 85-89
- 519 Efficacy and safety of allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning in patients under 55 years old. **2018**, 7, 82-89

- 518 Segmentation of skin lesions in chronic graft versus host disease photographs with fully convolutional networks. **2018**,
- 517 Outcome of Hematopoietic Stem Cell Transplantation in Wiskott-Aldrich Syndrome. **2018**, 25, 149-153
- 516 Graft Versus Host Disease (GHVD) in Critically Ill Oncologic Patients. **2019**, 1-17 1
- 515 Gastrointestinal Complications. **2019**, 381-386
- 514 Lower Genital Tract Precancer and Cancer in Hematopoietic Cell Transplant Survivors and the Role of HPV: A Systematic Review and Future Perspectives. **2019**, 1, 142-153
- 513 Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. **2019**, 1, 201-204
- 512 Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft--Host Disease Prophylaxis. **2019**, 1, 105-113 14
- 511 Current and Future Aspects of Smart Nanotheranostic Agents in Cancer Therapeutics. **2019**, 213-227
- 510 Noninfectious Pulmonary Manifestation of GVHD: Bronchiolitis Obliterans Syndrome. **2019**, 215-226
- 509 Lichenoid Inflammatory Phase of Chronic Skin GVHD. **2019**, 55-68
- 508 Systemic Diseases with an Increased Risk of Oral Squamous Cell Carcinoma. **2019**, 119-158
- 507 The thoracic air-leak syndrome (TALS): the frequency of occurrence and radiological signs in the structure of late non-infectious lung lesions in children after the allogeneic HSCT. **2019**, 18, 92-102 1
- 506 Extracorporeal Photopheresis in Hematopoietic Cell Transplantation. **2020**, 161-186
- 505 Evidence-based, Skin-directed Treatments for Cutaneous Chronic Graft-versus-host Disease. **2019**, 11, e6462 3
- 504 Graft-Versus-Host Disease. **2020**, 551-582
- 503 [Cutaneous manifestations of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation]. **2020**, 71, 557-568
- 502 Lung Function Predicts Outcome in Children With Obstructive Lung Disease After Hematopoietic Stem Cell Transplantation. **2021**, 43, e90-e94 1
- 501 Extramedullary leukemia relapse after allogeneic stem cell transplantation: a novel mechanism of immune escape?. **2020**, 12, 635-640

- 500 Possibilities of treating skin lesions in the graft versus host disease using the Pulsavac Plus wound repair system. **2020**, 7, 112-114
- 499 Lung transplantation for graft-versus-host disease after allogeneic stem cell transplantation: A report of two cases. **2020**, 28, 543-546
- 498 Corneal perforation in ocular graft-versus-host disease. **2021**, 24, 101224 0
- 497 Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. **2021** 1
- 496 Clinical Features of Cutaneous Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cells Transplantation in Children with Hemato-Oncological Diseases. **2020**, 19, 500-508
- 495 Graft Versus Host Disease: Management of Acute and Chronic Disease. **2021**, 1-30
- 494 Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. **2020**, 4, 6327-6335 0
- 493 Allogeneic haematopoietic stem cell transplantation with reduced-intensity conditioning in chronic myeloid leukaemia. **2020**, 65, 386-402
- 492 Graft Versus Host Disease (GHVD) in Critically Ill Oncologic Patients. **2020**, 249-265
- 491 ICU Complications of Hematopoietic Stem Cell Transplant, Including Graft vs Host Disease. **2020**, 599-609 1
- 490 Trichostasis Spinulosa as Manifestation of Cutaneous Graft versus Host Disease. **2020**, 32, 258-259
- 489 Lichenoid and Interface Dermatitis. **2020**, 41-92
- 488 Biology of Graft-Versus-Host Disease. **2020**, 1-19
- 487 Long-Term Follow-Up and Chronic Complications. **2020**, 1-25
- 486 Improved Clinical Outcome After Total Marrow Irradiation Conditioning Stem Cell Transplantation for Hematologic Malignancies. **2020**, 161-175 1
- 485 Allogeneic Transplant Overview and Matched Related Donor Transplant. **2020**, 1-34
- 484 Graft-versus-host disease. **2020**, 114-117.e1
- 483 Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center. **2021**, 17, 626-636 0

- 482 Skin damage after the hematopoietic stem cell transplantation. Literature review. **2020**, 19, 184-192 1
- 481 CD34+ selected peripheral blood Stem Cell Boost (SCB) for Poor Graft Function (PGF) or mixed chimerism in pediatric patients, after hematopoietic stem cell transplantation: Results of a retrospective multicenter study. **2021**, 25, e13909 1
- 480 Prevalence and Risk Factors Associated With Corneal Perforation in Chronic Ocular Graft-Versus-Host-Disease. **2021**, 40, 877-882 1
- 479 Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen. **2016**, 8, 653-61 9
- 478 Efficacy, Safety, and Practicality of Tacrolimus Monitoring after Bone Marrow Transplant: Assessment of a Change in Practice. **2020**, 73, 37-44
- 477 Different Immune Reconstitution between Cord Blood and Unrelated Bone Marrow Transplantation with Relation to Chronic Graft-versus-Host Disease. **2020**, 14, 1-10 0
- 476 [Application of low-dose ATG for GVHD prophylaxis in patients undergoing PBSCT aged over forty years old]. **2018**, 39, 292-298 0
- 475 [Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation]. **2019**, 40, 404-410
- 474 [Progress of chronic graft-versus-host disease]. **2016**, 37, 79-82 0
- 473 [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease]. **2019**, 40, 948-952 0
- 472 [The role of mesenchymal stem cells in allogeneic hematopoietic stem cell transplantation for patients with refractory severe aplastic anemia]. **2019**, 40, 726-731 1
- 471 [Treatment of 30 elderly patients with advanced myeloid neoplasm by allogeneic hematopoietic stem cell transplantation]. **2018**, 39, 629-633
- 470 [Comparison of different styles of allogeneic hematopoietic stem cell transplantation as first-line treatment treated with severe aplastic anemia in children and adolescents]. **2018**, 39, 184-189 0
- 469 [Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (III) -acute graft-versus-host disease (2020)]. **2020**, 41, 529-536 1
- 468 [Clinical features and risk factors analyses of patients with T cell large granular lymphocytosis following allo-HSCT]. **2020**, 41, 630-636 0
- 467 [Outcomes of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome without excess blasts]. **2020**, 41, 861-864
- 466 Follicular Graft Vs Host Reaction: A Rare Presentation. **2020**, 11, 988-990
- 465 Plasma levels of norepinephrine and expression levels of  $\alpha$ -adrenergic receptor gene correlate with the incidence of acute graft-versus-host disease. **2020**, 34, 151 2



464	[Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)]. <b>2021</b> , 42, 265-275	
463	[Correlation between immune reconstitution and chronic graft-versus-host disease after unrelated cord blood transplantation and sibling peripheral blood stem cell transplantation]. <b>2021</b> , 42, 466-473	
462	[Unrelated cord blood stem cell transplantation for high-risk/refractory childhood acute myeloid leukemia: a clinical analysis of 160 cases]. <b>2021</b> , 42, 549-554	
461	Polymyositis in a child with thalassemia after hematopoietic stem cell transplantation: A case report. <b>2021</b> , 100, e27388	
460	Expression ghitale des maladies systmiques. <b>2021</b> , 305-319	
459	Sodium thiosulfate-supplemented UW solution protects renal grafts against prolonged cold ischemia-reperfusion injury in a murine model of syngeneic kidney transplantation. <b>2021</b> , 145, 112435	2
458	Allogene hmatopoetische Stammzelltransplantation. <b>2022</b> , 59-67	
457	Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure. <b>2021</b> ,	1
456	Polymyositis in a child with thalassemia after hematopoietic stem cell transplantation. <b>2021</b> , 100, e27388	o
455	CAR-T cell therapy followed by unrelated cord blood transplantation for the treatment of relapsed/refractory B-cell ALL in children and young adults: superior survival but relatively high posttransplant relapse. <b>2021</b> , 28, 71.e1-71.e1	1
454	Outcome of haploidentical peripheral blood allografts utilizing post-transplant cyclophosphamide compared to matched sibling and unrelated donor bone marrow allografts in pediatric patients with hematological malignancies: A single center analysis. <b>2021</b> ,	o
453	Ruxolitinib as front-line therapy in graft versus host disease: Efficacy and safety in children. <b>2021</b> , 6, 166-166	o
452	Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 1-4	o
451	Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre. <b>2021</b> , 101, 155	o
450	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. <b>2021</b> ,	1
449	Late Effects After Haematopoietic Stem Cell Transplantation in ALL, Long-Term Follow-Up and Transition: A Step Into Adult Life.. <b>2021</b> , 9, 773895	1
448	The outcome and complications of total parenteral nutrition in pediatric hematopoietic stem cell transplantation. <b>2021</b> , e14198	o
447	Association of CD34 Cell Dose with 5-Year Overall Survival after Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. <b>2021</b> , 28, 88-88	2

- 446 Antinuclear antibodies produced in HLA-DR transgenic humanized mice developed chronic graft-versus-host disease. **2021**, 7, e08380
- 445 Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients. **2021**, 15, 4875-4883 0
- 444 Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part I. **2021**, 2
- 443 Uncommon Types of Gastritis and Gastropathies Including Anti-parietal Cell, GVHD, Reactive and Granulomatous Gastritis. **2022**, 201-218
- 442 Graft-versus-host disease in the female genital tract: a prospective cohort study. **2021**, 1
- 441 Effect of donor characteristics on T cell-replete haploidentical stem cell transplantation over the last 10 years at a single institution. **2021**, 1
- 440 Follicular graft Vs host reaction: A rare presentation. **2020**, 11, 988
- 439 A New Prognostic Scoring System (BRIGHT) Predicts Mortality of Septic Shock after Allogeneic Hematopoietic Stem Cell Transplantation.
- 438 Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin.. **2021**, 12, 20406207211063783 0
- 437 A rare case report of graft-versus-host disease-related cutaneous horns of the lower lip.. **2022**, 21, 59-62
- 436 Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area.. **2022**, 1 0
- 435 Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.. **2021**, 11, 805514 2
- 434 Expression of transforming growth factor  $\beta$  pathway components in chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.. **2021**, 70, 101514
- 433 Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.. **2021**, 70, 101520 2
- 432 A single institute validation study comparing the international chronic ocular graft-versus-host disease consensus group diagnostic criteria with clinical parameters.. **2021**, 24, 12-14 1
- 431 Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation. **2021**,
- 430 Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability.. **2022**, 6, e29393
- 429 Risk Factors of Graft-Versus-Host Disease in the Iranian Allogeneic Hematopoietic Stem Cell Transplantation: A 10-Year Experience.. **2021**, 35, 145 0

428	Home-Based Hematopoietic Cell Transplantation in the United States: Home HCT in the US.. <b>2022,</b>	0
427	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. <b>2021, 9, 784024</b>	2
426	RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea.. <b>2022,</b>	0
425	Ophthalmic manifestations are associated with reduced tear lymphotoxin- $\beta$ levels in chronic ocular graft-versus-host disease.. <b>2022, 22, 18</b>	0
424	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.. <b>2022, JCO2101755</b>	4
423	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft--host disease after haploidentical allogeneic hematopoietic stem cell transplantation.. <b>2022, 13, 20406207211072838</b>	2
422	Regenerating Islet-Derived 3-alpha is a Prognostic Biomarker for Gastrointestinal Chronic Graft-Versus-Host Disease.. <b>2022,</b>	1
421	Metabolomics: a novel way to diagnose cGVHD?. <b>2022, 139, 161-162</b>	
420	Oral Graft-Versus-Host Disease. <b>2022, 213-225</b>	
419	Rational use of chronic graft-versus-host treatment alternatives: A systematic review.. <b>2022, 103371</b>	
418	Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC.. <b>2022,</b>	0
417	Oral chronic GVHD after allogeneic stem cell transplantation without total body irradiation performed at a young age.. <b>2022, 30, 4121</b>	1
416	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.. <b>2022, 9, e14-e25</b>	2
415	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.. <b>2021, 11, 773394</b>	1
414	PTCy-based Haploidentical vs Matched Unrelated Donor Peripheral Blood HSCT Using Myeloablative Targeted Busulfan-based Conditioning for Pediatric Acute Leukemia.. <b>2022,</b>	0
413	Incidence and Risk Factors for Acute Kidney Injury after Allogeneic Stem Cell Transplantation: A Prospective Study.. <b>2022, 10,</b>	0
412	Myeloablative Conditioning Regimen in Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide in Children With High-risk Hematologic Malignancies.. <b>2022,</b>	
411	Outcomes following DLI in patients with haematological malignancies: Donor characteristics matter.. <b>2022,</b>	

410	Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.. <b>2022</b> , 103367	1
409	Three FDA-approved therapies for chronic GVHD.. <b>2022</b> ,	2
408	Basiliximab for steroid-refractory acute graft-versus-host disease: a real-world analysis.. <b>2022</b> ,	2
407	Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.. <b>2022</b> ,	
406	Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants.. <b>2022</b> ,	0
405	Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease.. <b>2022</b> , 25, 103592	2
404	Established and Emerging Treatments of Skin GvHD.. <b>2022</b> , 13, 838494	
403	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis.. <b>2022</b> ,	
402	Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management.. <b>2022</b> , 71, 101524	0
401	FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.. <b>2022</b> ,	0
400	Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial.. <b>2022</b> ,	0
399	HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. <b>2022</b> , 3, 51-67	
398	Abatacept-based Graft-Versus-Host Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant in a High-risk Cohort.. <b>2022</b> ,	0
397	Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoietic stem cell transplantation.. <b>2022</b> ,	
396	Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.. <b>2022</b> ,	
395	Chronic graft versus host disease: atypical vesicular presentation. <b>2022</b> , 156,	
394	Multiple breath washout testing to identify pulmonary chronic graft versus host disease in children after haematopoietic stem cell transplantation.. <b>2022</b> ,	0
393	Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis.. <b>2022</b> , 31, 9636897221079739	0

392	Neurological complications of hematopoietic stem cell transplantation. <b>2022</b> , 501-513	
391	Neurologic complications in the treatment of childhood malignancies. <b>2022</b> , 433-462	
390	Hematopoietic Stem Cell Transplantation in Nepal: international partnership, implementation steps and clinical outcomes.. <b>2022</b> ,	2
389	Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study.. <b>2022</b> , 11,	0
388	Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia.. <b>2022</b> , 1	
387	Tear Cytokines as Biomarkers for Acute Ocular Graft-Versus-Host Disease.. <b>2022</b> ,	
386	Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation.. <b>2022</b> , 23,	
385	Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases.. <b>2022</b> ,	0
384	How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?. <b>2022</b> , 103405	0
383	Impact of donor-to-recipient ABO mismatch on outcomes of ATG-based peripheral blood stem cell-derived myeloablative conditioning haploidentical stem cell transplantation.. <b>2022</b> ,	0
382	Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.. <b>2022</b> , 10, 808103	1
381	Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia.. <b>2022</b> , 22, 89	0
380	Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.. <b>2022</b> ,	0
379	Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.. <b>2022</b> , 1	0
378	Risk of oral cancer in patients with graft-vs-host disease: A systematic review and meta-analysis.. <b>2022</b> ,	1
377	Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin.. <b>2022</b> ,	
376	The Two-Step Allogeneic Stem Cell Transplant Approach Results in Rapid Engraftment and Excellent Outcomes in Patients with Lymphoid Malignancies.. <b>2021</b> ,	
375	CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.. <b>2022</b> ,	1

- 374 Predictors and outcomes of flares in chronic graft-versus-host disease.. **2022**, ○
- 373 Phototherapy and topical treatments for cutaneous graft versus host disease in hematopoietic stem cell transplantation patients: A scoping review.. **2022**, 1
- 372 A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation.. **2022**, 12, 862526 ○
- 371 Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.. **2022**, 15, 22 ○
- 370 Performance of high-frequency ultrasound in the evaluation of skin involvement in cutaneous chronic graft-versus-host disease: a preliminary report.. **2022**,
- 369 A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.. **2022**, ○
- 368 Effect of donor lymphocyte infusion from two types of donors on Mixed Chimerism with Secondary Graft Failure after allogeneic haematopoietic stem cell transplantation.. **2021**, ○
- 367 Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates.. **2022**, 14, eabm8646 ○
- 366 Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study.. **2022**, 1
- 365 Allogeneic Hematopoietic Stem Cell Transplantation For Heavily Pretreated Patients With Mycosis Fungoides and Sezary Syndrome.. **2022**, e15447
- 364 Artificial intelligence recognition of cutaneous chronic graft-versus-host disease by a deep learning neural network.. **2022**, ○
- 363 The impact of second-donor lymphocyte infusion on secondary graft failure after allogeneic hematopoietic stem cell transplantation through activation of Foxp3 and regulatory T cells.. **2022**,
- 362 Post-transplant Complication With TAFRO Features in a Patient With Acute Myeloid Leukemia.. **2022**, 14, e23688
- 361 Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.. **2021**, ○
- 360 Morbilliform Eruptions in the Hospitalized Child.. **2022**, 40, 191-202
- 359 Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.. **2022**, 5, e226114 ○
- 358 Increased risk of nonrelapse mortality post T-cell-replete haploidentical stem cell transplantation in patients with recurrence of acute graft-versus-host disease.. **2022**,
- 357 HAPLOIDENTICAL STEM CELL TRANSPLANTATION AFTER TCR AND CD19 CELLS DEPLETION IN CHILDREN WITH CONGENITAL NON-MALIGNANT DISEASE.. **2022**, 1

356	Chronic kidney disease, survival and graft-versus-host-disease/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant.	
355	Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission.. <b>2022</b> ,	0
354	Chronic graft-versus-host disease-related polymyositis and myocarditis: A case report and review of the literature.. <b>2022</b> , 72, 101598	0
353	Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.. <b>2022</b> , 70, 103343	1
352	Impaired right ventricular function in long-term survivors of allogeneic haematopoietic stem-cell transplantation.. <b>2021</b> , 8,	0
351	Low- and High-Attenuation Lung Volume in Quantitative Chest CT in Children without Lung Disease.. <b>2021</b> , 8,	
350	Results of a multicenter phase I/II trial of TCR $\alpha$ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients.. <b>2021</b> ,	6
349	Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study.. <b>2021</b> , 1-9	0
348	Long-Term Mixed Chimerism After / T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms.. <b>2021</b> , 11, 776946	0
347	A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.. <b>2021</b> , 9, 774853	
346	Late follow-up of genital and ophthalmologic chronic graft-versus-host disease in females after allogeneic stem cell transplantation.. <b>2021</b> ,	0
345	Extracorporeal photopheresis in chronic graft-versus-host disease: clinical description and economic study.. <b>2021</b> ,	
344	Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors.. <b>2021</b> ,	0
343	Updates in chronic graft-versus-host disease. <b>2021</b> , 2021, 648-654	1
342	Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients.. <b>2021</b> , 12, 774442	
341	Value of Autoantibody Expression During Long-Term Follow-Up in Paediatric ALL Patients After Allogeneic Haematopoietic Stem Cell Transplantation.. <b>2021</b> , 9, 788360	
340	Variable impact of graft CD3 cell content on graft versus host disease in hematopoietic stem cell transplant recipients: Is the role of donor CD3 cells overestimated?. <b>2021</b> , 103349	
339	Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.. <b>2022</b> ,	1

- 338 Multiple mononeuritis as a manifestation of graft versus host disease. **2022,**
- 337 Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease.. **2022,**
- 336 The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR.. **2022,** ○
- 335 Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.. **2022,** ○
- 334 Post-transplant strategies to improve relapse-free survival in childhood leukemia: Whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect.. **2022,** e14293 ○
- 333 MicroRNA serum profiles and chronic graft versus host disease.. **2022,** ○
- 332 The Relevance of Skin Biopsies in General Internal Medicine: Facts and Myths.. **2022,** 1
- 331 Ocular Graft Versus Host Disease: Just a Severe Form of Dry Eye or Something More?. 1
- 330 Feasibility and efficacy of partially replacing post-transplant cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantation.. **2022,** ○
- 329 Early reconstitution of lymphocytes after allo-HSCT affects chronic GVHD.
- 328 Image\_1.TIF. **2018,**
- 327 Table\_1.docx. **2018,**
- 326 Data\_Sheet\_1.PDF. **2019,**
- 325 table\_1.xlsx. **2018,**
- 324 Table\_1.DOCX. **2019,**
- 323 Table\_2.DOCX. **2019,**
- 322 Comparative analysis of Decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation.. **2022,**
- 321 Combination of Haploidentical Hematopoietic Stem Cell Transplantation with Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Severe Aplastic Anemia: a Retrospective, Controlled Study.. **2022,**



- 320 Allogeneic haematopoietic stem cell transplantation resets T- and B-cell compartments in sickle cell disease patients.. **2022**, 11, e1389
- 319 Graft Versus Host Disease. **2022**, 7557-7579
- 318 Gene expression profile of chronic oral graft-versus-host disease.. **2022**, 17, e0267325
- 317 Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.. **2022**, 13, 879030
- 316 CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.. **2022**,
- 315 Health-related quality of life in pediatric patients with  $\beta$ -thalassemia major after hematopoietic stem cell transplantation.. **2022**, ○
- 314 Pediatric vulvovaginal graft-versus-host disease: A retrospective cohort study and literature review.. **2022**, ○
- 313 A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.. **2022**, ○
- 312 Abnormal liver tests are not sufficient for diagnosis of hepatic graft-versus-host disease in critically ill patients.. **2022**,
- 311 Ocular Graft-versus-Host Disease Underdiagnosis: A Survey Study.. **2022**, 16, 1419-1426
- 310 Lung Function Monitoring After Lung Transplantation and Allogeneic Hematopoietic Stem Cell Transplantation.. **2022**, ○
- 309 Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation.. **2022**, 1 ○
- 308 Pulmonary graft-versus-host disease and chronic lung allograft dysfunction: two sides of the same coin?. **2022**, ○
- 307 Pathological features of inflammatory myopathy as a manifestation of chronic graft-versus-host disease after allogeneic bone marrow transplantation.. **2022**,
- 306 Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.. **2022**, ○
- 305 -Evaluating differential expression of fibrosis-related genes and their correlation with blood vessel density in chronic cutaneous graft-versus-host disease. **2022**,
- 304 Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide.. **2022**, ○
- 303 The ISHLT Chronic Lung Allograft Dysfunction Consensus Criteria is Applicable to Pulmonary Chronic Graft-versus-Host Disease.. **2022**, ○

- 302 Risk factors associated with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. **2022**, 4, 83-88 1
- 301 Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis.. **2022**,
- 300 Features of EpsteinBarr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen. **2022**, 12, 0
- 299 The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia.
- 298 ELTROMBOPAG MAY INDUCE BONE MARROW FIBROSIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH PROLONGED THROMBOCYTOPENIA. **2022**, 106870 0
- 297 Organ-specific response after low-dose interleukin-2 therapy for steroid refractory chronic Graft-versus-Host Disease. 0
- 296 Oral Chronic Graft-Versus-Host Disease. **2022**, 3,
- 295 Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?. **2022**, 0
- 294 Towards a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. **2022**, 1
- 293 Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. **2022**, 6, e730
- 292 Comparison of pulmonary toxicity after total body irradiation- and busulfan-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation for pediatric patients. **2022**, 0
- 291 Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study. 0
- 290 Tongue graft-versus-host disease: remission with ruxolitinib. **2022**, 15, e247888
- 289 Pediatric acute myeloid leukemia patients with KMT2A rearrangements: a single-center retrospective study. **2022**, 27, 583-589 0
- 288 Outcomes of scleral lenses for dry eye disease in chronic ocular graft-versus-host disease. **2022**, 101721 0
- 287 Significance of alveolar nitric oxide concentration in the airway of patients with organizing pneumonia after allogeneic hematopoietic stem cell transplantation.
- 286 Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. **2022**, 0
- 285 The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. 0

- 284 Pruritic rash following haploidentical stem cell transplantation.
- 283 Pancreatic atrophy and recovery after allogeneic hematopoietic cell transplantation.
- 282 Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease. ○
- 281 IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity. **2022**, 11, ○
- 280 Graft Versus Host Disease and Dry Eye Disease. **2023**, 107-117
- 279 Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. **2022**, 13, 204062072210908
- 278 A Case of Chronic Graft-versus-host Disease-associated Membranous Nephropathy Following Bone Marrow Transplantation, Successfully Treated with Rituximab. **2022**, ○
- 277 Compromiso gastrointestinal por enfermedad de injerto contra huésped. **2022**, 37, 225-232
- 276 The impact of pre-transplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents.
- 275 Lower expression of NOTCH components in peripheral blood mononuclear cells of allogeneic hematopoietic cell transplant patients. **2022**,
- 274 Outcomes and risk factors of hemorrhagic cystitis in pediatric allogeneic hematopoietic stem cell transplantation recipients using different graft source and condition with severe aplastic anemia. **2022**, 27, 714-722 ○
- 273 The importance of intermediate-dose Valacyclovir in primary CMV prophylaxis after Allogeneic-stem cell transplantation, and the advantages of step-wise pre-emptive treatment in CMV reactivation. **2022**, 9, 324-333
- 272 Risk factors for lower respiratory tract disease and outcomes in allogeneic hematopoietic stem cell transplantation recipients with influenza virus infection. **2022**, ○
- 271 J-SUPPORT research policy for oral mucositis associated with cancer treatment.
- 270 Higher Dose of CD34+ cells Promotes Early Reconstitution of Natural Killer Cells and Is Associated with Better Outcomes After Unmanipulated Hematopoietic Stem Cell Transplantation for Myeloid Malignancies. **2022**, ○
- 269 Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States. **2022**, 25, 857-863
- 268 Low-intensity immunosuppressive therapy for chronic graft-versus-host disease. **2022**, ○
- 267 Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study. 1-7

- 266 Salivary Gland Dysfunction Secondary to Cancer Treatment. 3, 1
- 265 Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. **2022**,
- 264 Efficacy of hematopoietic stem cell transplantation in the treatment of children with non-severe aplastic anemia.
- 263 Impact of allogeneic stem cell transplantation in childhood and adolescence on quality of adulthood life: A case-control study.
- 262 Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents. **2022**, 2022,
- 261 Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. 00185-2022 3
- 260 Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes. 0
- 259 Expert opinion on emerging drugs for lung chronic graft-versus-host disease. 1-3
- 258 Late pulmonary complications related to cancer treatment in children. 0
- 257 The results of ten years' experience in allogeneic hematopoietic stem cell transplantation at the Russian Children's Clinical Hospital. **2022**, 21, 22-31
- 256 Pediatric Graft-Versus-Host Disease. **2022**,
- 255 Experience in the use of 5-azacytidine, bortezomib and valproic acid for the prevention of leukemia relapses in children after ab-T cell-depleted hematopoietic stem cell transplantation. **2022**, 21, 32-41
- 254 High response rate and corticosteroid sparing with arsenic trioxide-based first-line therapy in cGvHD after allo-HSCT. **2022**,
- 253 Characteristics of Graft-versus-Host Disease (GvHD) after Post-transplant Cyclophosphamide versus Conventional GvHD Prophylaxis. **2022**, 0
- 252 Mapping research trends of chronic ocular graft-versus-host disease from 2009 to 2020: a bibliometric analysis. 0
- 251 Extracorporeal photopheresis in the treatment of chronic graft-versus-host-disease. **2022**, 67, 202-215
- 250 Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment. 12, 0
- 249 Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation. 13,

- 248 Reduced exercise capacity is associated with left ventricular systolic dysfunction in long-term survivors of allogeneic hematopoietic stem-cell transplantation. ○
- 247 The great Lazarus Graft-versus-host-disease patient!.
- 246 Immunohistopathology of Oral Mucosal Chronic Graft-versus-Host Disease Severity and Duration. ○
- 245 Clinical Manifestation of Infectious Keratitis in Ocular Graft Versus Host Disease. **2022**, 63, 592-601
- 244 Third-party CMV- and EBV-specific T cells for first viral reactivation after allogeneic stem cell transplant. ○
- 243 Ruxolitinib Treatment in an Adolescent With Chronic Graft-Versus-Host Disease Mimicking Eosinophilic Gastrointestinal Disorders: A Case Report. **2022**,
- 242 Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. ○
- 241 Tear Cytokines Associated With Therapeutic Effects in Chronic Ocular Graft-Versus-Host Disease. **2022**, Publish Ahead of Print, ○
- 240 Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. **2022**, 6, 4098-4106 1
- 239 Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients. 12,
- 238 Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. 1
- 237 Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. **2022**, ○
- 236 Epidemiology of lower respiratory tract infections and community-acquired respiratory viruses in patients with bronchiolitis obliterans syndrome after hematopoietic cell transplant: a retrospective cohort study. **2022**,
- 235 Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. **2022**, ○
- 234 Comparison of Outcomes of Donor Lymphocyte Infusions With or Without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic HSCT.
- 233 Characterization of Hepatic Dysfunction in subjects diagnosed with Chronic GVHD by NIH Consensus Criteria. **2022**, ○
- 232 A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies. **2022**, 31, 096368972211120
- 231 Long-term clinical outcomes and predictive factors in patients with chronic ocular graft-versus-host disease. **2022**, 12,

- 230 Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. **2022,** 2
- 229 Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. **2022,** 1
- 228 Ocular Chronic Graft-Versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes After Allogeneic Haematopoietic Cell Transplantation. **2022,**
- 227 Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group. 0
- 226 Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies.
- 225 High Risk of Recurrence of Malignancy Noted in 4-day rATG Regimen after Allogeneic PBSCT from Matched Sibling Donors.. **2022,**
- 224 Clinically amyopathic dermatomyositis manifested after the allogeneic haematopoietic stem cell transplantation: Case presentation and literature review.
- 223 Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. **2022, 1033-60** 0
- 222 Repeated Occurrence and Recurrence of Secondary Oral Solid Cancers after Hematopoietic Stem Cell Transplantation for Leukaemia: Long-Term Follow-Up. **2022, 2022, 1-6**
- 221 Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review. **2022, 62,** 0
- 220 Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation. **2022,** 12,
- 219 Long-term transplant outcomes after allogeneic hematopoietic transplant in pediatric patients with hematological malignancies are influenced by severe chronic graft vs. host disease and immune reconstitution. 10,
- 218 The effect of intensity of conditioning regimen on the outcome of HSCT in children with sickle cell disease. 0
- 217 An uncommon presentation of paediatric chronic graft-versus-host disease after umbilical cord blood transplantation: True lichen planus-like lesions. 1-3
- 216 Multicenter prospective validation study for international chronic ocular graft-versus-host disease consensus diagnostic criteria. **2022, 26, 200-208** 0
- 215 Clinical features of non-infectious pulmonary complications after donor lymphocyte infusion in post-transplant patients: The Nagasaki Transplant Group Experience. **2022, 75, 101707** 0
- 214 A Case of Possible Chronic Graft-versus-host Disease in the Central Nervous System Manifesting as Cerebellar Ataxia after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. **2022,** 0
- 213 Multiple oral squamous cell carcinoma 6 years after allogeneic stem cell transplantation complicated with chronic graft-versus-host disease: A case report. **2022, 10, 2050313X2211182** 0

- 212 Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD. **2022**, 31, 096368972211137 ○
- 211 Effect of azithromycin on bronchiolitis obliterans syndrome in posttransplant recipients: A systematic review and meta-analysis. **2022**, 101, e29160 ○
- 210 Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study. **2022**, ○
- 209 Haplo-Peripheral Blood Stem Cell Plus Cord Blood Grafts for Hematologic Malignancies Might Lead to Lower Relapse Compared with Haplo-Peripheral Blood Stem Cell Plus Bone Marrow Grafts. **2022**, ○
- 208 Late Effects of Severe Acute Graft-versus-Host Disease on Quality of Life, Medical Comorbidities, and Survival. **2022**, ○
- 207 Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores. **2022**, 14, 4266 ○
- 206 Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases. 13, ○
- 205 Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease. 13, ○
- 204 Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease among diabetes mellitus patients undergoing allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective study. ○
- 203 Mitigation of gastrointestinal graft versus host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. ○
- 202 Extracorporeal photopheresis in acute and chronic steroid-refractory graft-versus-host disease: an evolving treatment landscape. ○
- 201 Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation. ○
- 200 Successful treatment of severe post hematopoietic stem cell transplantation bronchiolitis obliterans syndrome with lung transplantation in a patient with multi-organ chronic graft-versus-host disease. **2022**, 10, ○
- 199 Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. ○
- 198 Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study. 1-8 ○
- 197 Role of extracorporeal photopheresis in the management of children with graft-vs-host disease. ○
- 196 Clinical value of plasma and peripheral blood mononuclear cells EpsteinBarr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation. 12, ○
- 195 Corneal perforation associated with ocular graft-versus-host disease. 12, ○

- 194 A plethora of ocular surface manifestations in a multidisciplinary ocular graft-versus-host disease unit. **2022**, 12, ○
- 193 Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression. **2022**, ○
- 192 The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study. 13, ○
- 191 Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study. 1-10 ○
- 190 Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation. 13, ○
- 189 The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective study. ○
- 188 Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation. 13, ○
- 187 Post-transplant cyclophosphamide versus antithymocyte globulin as GVHD prophylaxis for 10/10 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.. ○
- 186 Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group. ○
- 185 Healthy-like CD4+ Regulatory and CD4+ Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion. **2022**, 23, 10914 ○
- 184 Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials. 1
- 183 Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD. **2022**, 15, 1100 ○
- 182 Unrelated umbilical cord blood can improve the prognosis of haploidentical hematopoietic stem cell transplantation. **2022**, 13, ○
- 181 Prevention of non-infectious pulmonary complications after intra-bone marrow stem cell transplantation in mice. **2022**, 17, e0273749 ○
- 180 Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse. 13, ○
- 179 Metabolic Dysregulation in Adult Survivors of Pediatric Hematopoietic Stem Cell Transplantation: The Role of Incretins. ○
- 178 Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabineBusulfanCytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. ○
- 177 Pulmonary Manifestations and Vascular Changes in Pediatric Transplant Associated Thrombotic Microangiopathy. **2022**, ○



- 176 Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-versus-host disease in pediatric patients with acquired severe aplastic anemia. **2022**, 13, 204062072211344 ○
- 175 Hematopoietic Cell Transplantation. 1-13 ○
- 174 Transplantation for myeloid neoplasms with antecedent solid tumor. ○
- 173 Risk factors and survival of refractory cytomegalovirus reactivation after allogeneic peripheral blood stem cell transplantation. **2022**, ○
- 172 Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder. **2022**, ○
- 171 Sleep-related breathing disorder in non-infectious pulmonary complications after pediatric allogeneic stem cell transplantation. ○
- 170 Respiratory Complications. 1-37 ○
- 169 Interstitial lung diseases after hematopoietic stem cell transplantation: New pattern of lung chronic graft-versus-host disease?. ○
- 168 Chronic gvhd dictionaryEurograft cost action initiative consensus report. ○
- 167 Implementation of Routine Endoscopy with Narrow Band Imaging in the Evaluation of Oral and Upper Airways Lesions in Oral Chronic Graft-Versus-Host Disease: A Preliminary Study. **2022**, 12, 1628 ○
- 166 Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review. 13, ○
- 165 Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior OS for patients with long-term survival. **2022**, 13, ○
- 164 Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC. ○
- 163 Haploidentical transplant for paediatric patients with severe thalassaemia using post-transplant cyclophosphamide and methotrexate: A prospectively registered multicentre trial from the Bone Marrow Failure Working Group of Hunan Province, China. ○
- 162 Two decades of stem cell transplantation in patients with Fanconi anemia: Analysis of factors affecting transplant outcomes. ○
- 161 Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients. **2022**, ○
- 160 Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT. 1
- 159 Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis. ○

- 158 Haploidentical hemopoietic cell transplantation for myelofibrosis, in ruxolitinib era. **2022**, ○
- 157 Gastrointestinal and Hepatic Complications in Cancer Patients. 1-18 ○
- 156 Bortezomib maintenance after allogeneic transplantation in newly diagnosed myeloma patients results in decreased incidence and severity of chronic GVHD. **2022**, ○
- 155 Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors. ○
- 154 Phase I trial of myeloablative conditioning with 3-day total marrow and lymphoid irradiation for leukemia. 1
- 153 Musculoskeletal Chronic Graft versus Host Disease: A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature. **2022**, 29, 8415-8430 ○
- 152 Granulomatous myopathy: Sarcoidosis and beyond. ○
- 151 Non-Expert Markings of Active Chronic Graft-Versus-Host Disease Photographs: Optimal Metrics of Training Effects. ○
- 150 Oral lichen planus and related lesions. What should we accept based on the available evidence?. ○
- 149 Significance of omitting day 11 mini-dose methotrexate for GVHD prophylaxis after unrelated bone marrow transplantation. **2022**, ○
- 148 Risk stratification system for skin and soft tissue infections after allogeneic hematopoietic stem cell transplantation: PAH risk score. ○
- 147 Ibrutinib: Pediatric First Approval. 1
- 146 Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies undergoing matched sibling or alternative donor transplantation. ○
- 145 Patient-reported symptom burden and impact on daily activities in chronic graft-versus-host disease. ○
- 144 Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein-Barr virus infection. ○
- 143 Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia. **2022**, ○
- 142 The ocular graft-versus-host disease: the path from current knowledge to future managements. ○
- 141 Impact of posttransplant cyclophosphamide on the outcome of patients undergoing unrelated single-unit umbilical cord blood transplantation for pediatric acute leukemia. **2022**, 22, ○

- 140 Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors. **2022**, 31, 096368972211391 ○
- 139 Correlative factors of ocular surface lesions after allogeneic hematopoietic stem cell transplantation: A retrospective study. 12, ○
- 138 Successful Management of Infectious Crystalline Keratopathy with Intrastromal Antibiotic Injections. **2022**, 2022, 1-6 ○
- 137 Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. **2022**, 58, 1722 ○
- 136 Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation. **2022**, ○
- 135 Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation. **2022**, 17, ○
- 134 A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease. 1-11 ○
- 133 Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study. **2022**, ○
- 132 Chronic graft-vs-host disease: Current understanding of disease and treatment landscape. **2022**, 28, S2-S12 ○
- 131 Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. ○
- 130 Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment. **2022**, ○
- 129 Long-term survivors demonstrate superior quality of life after haploidentical stem cell transplantation to matched sibling donor transplantation. **2022**, 20, ○
- 128 Immune Ablation and Stem Cell Rescue in Two Pediatric Patients with Progressive Severe Chronic Graft-Versus-Host Disease. **2022**, 23, 15403 ○
- 127 Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. ○
- 126 Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation. ○
- 125 A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease. **2022**, ○
- 124 Ruxolitinib-induced Reactivation of Cytomegalovirus and Epstein-Barr Virus in Graft-versus-host Disease. **2022**, 107005 ○
- 123 Okuläre Graft-Versus-Host Erkrankung. ○

- 122 Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT. **2022**, 17, ○
- 121 Seeing the unseen: Use of a modified OSDI questionnaire to accurately detect chronic ocular GVHD in a hematology clinic. **2022**, ○
- 120 Donor Genetic Predisposition to High Interleukin-10 Production Appears Protective against Acute Graft-Versus-Host Disease. **2022**, 23, 15888 ○
- 119 The predictive value of pulmonary function test before transplantation for chronic pulmonary graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation. **2022**, 22, ○
- 118 Regulatory T-cells and allogeneic hematopoietic stem cell transplantation. **2022**, 14, 462-475 ○
- 117 HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. **2022**, ○
- 116 Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation. ○
- 115 Risk Factors and Outcomes of Nocardiosis in Hematopoietic Stem Cell Transplant Recipients. **2022**, ○
- 114 Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. **2023**, 55, 388-400 ○
- 113 Human effectors of acute and chronic GVHD overexpress CD83 and predict mortality. ○
- 112 Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study. 13, ○
- 111 A Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation. **2023**, ○
- 110 Critical digital ischemia and biliary cholangitis related to graft versus host disease: A case report and systematic literature review. **2023**, 102, e32495 ○
- 109 Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. ○
- 108 Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation. **2023**, 12, 458 ○
- 107 IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. **2023**, ○
- 106 Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iINTEGRATE Study. 1
- 105 Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. ○

- 104 Prognostic impact of the simple L-index and absolute lymphocyte count early after allogeneic hematopoietic stem cell transplantation. **2023**, ○
- 103 CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results. 12, ○
- 102 Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival. **2023**, ○
- 101 Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. ○
- 100 Thoracic air leak syndrome as the sole manifestation of chronic lung graft-versus-host disease: a case report. **2023**, 17, ○
- 99 Conjunctival inflammation and dry eye symptoms at day 100 post-transplantation do not predict risk for chronic graft-versus-host disease. **2023**, 0 ○
- 98 Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric  $\beta$ -Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study. ○
- 97 Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. ○
- 96 Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission. ○
- 95 Bronchiolitis Obliterans. **2016**, 1-12 ○
- 94 Enfermedad injerto contra receptor crónica: revisión sistemática de la afectación articular y fascial. **2023**, ○
- 93 A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors. **2023**, 23, ○
- 92 Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation. ○
- 91 Indications plus rares de transplantation pulmonaire et circonstances particulières : réaction du greffon contre l'hôte pulmonaire post allogreffe de moelle osseuse. **2023**, ○
- 90 Recent advances in ocular graft-versus-host disease. 14, ○
- 89 Ibrutinib Induces a Dramatic Improvement for Idiopathic Refractory Ascites Following Allogeneic Hematopoietic Cell Transplantation. **2023**, ○
- 88 Transplantation. **2023**, 599-674 ○
- 87 Incidence of cutaneous graft-versus-host disease in a Singapore academic medical centre  $\square$  retrospective cohort study. ○

- 86 Graft-Versus-Host Disease: an Update on Functional Implications and Rehabilitation Interventions. ○
- 85 Hematopoietic stem cell transplant start-up in Iraqi Kurdistan: results on thalassemia patients and analysis of the methodology. **2023**, ○
- 84 Pericardial effusion as a purported manifestation of graft versus host disease following allogeneic hematopoietic cell transplantation. **2023**, ○
- 83 The effect of granulocyte-colony stimulating factor, decitabine, and busulfan cyclophosphamide versus busulfan cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome ○
- 82 Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates. **2023**, ○
- 81 Insights and strategies to promote immune tolerance in allogeneic hematopoietic stem cell transplantation recipients. **2023**, 329-360 ○
- 80 Novel pre-clinical mouse models for chronic Graft-versus-Host Disease. 13, ○
- 79 Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up. **2023**, 32, 096368972311632 ○
- 78 Pediatric chronic graft-versus-host disease-related dry eye disease and the diagnostic association of potential clinical findings. **2023**, 13, ○
- 77 Impact of Chronic Graft-Versus-Host Disease (GVHD) on Patients' Employment, Income, and Informal Caregiver Burden: Findings From the Living With Chronic GVHD Patient Survey. **2023**, ○
- 76 Phytochemical components and GC/MS analysis of *Petiveria alliacea* L. fractions and volatile oils. **2023**, ○
- 75 Lichenoid Lesions of the Oral Mucosa. **2023**, 35, 189-202 ○
- 74 Dermatologic complications in transplantation and cellular therapy for acute leukemia. **2023**, 36, 101464 ○
- 73 Complications and outcomes of gastrostomy versus nasogastric tube feeding in paediatric allogeneic bone marrow transplant: A prospective cohort study. **2023**, 55, 58-70 ○
- 72 Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A Kanto Study Group for Cell Therapy multicenter analysis. **2023**, 131, 79-86 ○
- 71 Hepatobiliary disease after bone marrow transplant. **2023**, 17, 129-143 ○
- 70 Preemptive interferon- $\gamma$  therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis. 14, ○
- 69 Clinical Benefit of Low-Dose Antithymocyte Globulin-Thymoglobulin as Graft-versus-Host Disease Prophylaxis in Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Identical Donors. **2023**, ○

- 68 Impulse oscillometry system for assessing small airway dysfunction in pediatric bronchiolitis obliterans; association with conventional pulmonary function tests. **2023**, 18, e0280309 ○
- 67 Chronic graft-versus-host disease in pediatric patients: Differences and challenges. **2023**, 101054 ○
- 66 A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant. **2023**, ○
- 65 Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. **2023**, ○
- 64 Assessment of Corneal Epithelial Changes and Related Factors in Ocular Chronic Graft-Versus-Host Disease (GVHD) by in Vivo Confocal Microscopy. 1-9 ○
- 63 A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation. **2023**, ○
- 62 Oral complications in a paediatric graft versus host disease (GVHD) clinic: A retrospective study. ○
- 61 Case report: HLA-haploidentical HSCT rescued with donor lymphocyte infusions in a patient with X-linked chronic granulomatous disease. 14, ○
- 60 Elevated ADA2 Enzyme Activity at the Onset of Chronic Graft-versus-Host Disease in Children. **2023**, ○
- 59 Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease. 10, ○
- 58 Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. **2023**, 41, 1820-1824 ○
- 57 Efficacy of Azacitidine and Prophylactic Donor Lymphocyte Infusion after HSCT in Pediatric Patients with Acute Myelogenous Leukemia: A Retrospective Pre-Post Study. **2023**, ○
- 56 Post-transplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher T cell dose. ○
- 55 Current Concepts and Future Prospects in Immune-Mediated Myopathies. **2023**, 161-189 ○
- 54 Emergency Department Utilization Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Longitudinal Analysis of 557 Patients. **2023**, ○
- 53 Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC. **2023**, ○
- 52 Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer. **2023**, 42, 101824 ○
- 51 Systemic Non-infectious Hepatitis. **2023**, 557-579 ○

- 50 BleedHD<sup>®</sup> new electronic assessment tool for grading chronic graft-versus-host disease validated in a multicenter and multiprofessional setting. ○
- 49 Ocular graft-versus-host disease (oGVHD): From A to Z. **2023**, ○
- 48 Comparison of NK alloreactivity prediction models based on KIR-MHC interactions in haematopoietic stem cell transplantation. 14, ○
- 47 Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease. **2023**, 159, 393 ○
- 46 Impact of allogeneic stem cell transplantation on thyroid function. ○
- 45 Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients. **2023**, 6, e202201786 ○
- 44 Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease. **2023**, 18, e0282753 ○
- 43 A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia. **2023**, 15, 1666 ○
- 42 Impact of Lymphocyte Subsets of Grafts on the Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation. **2023**, 32, 096368972311570 ○
- 41 Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. ○
- 40 Bacterial Bloodstream Infections after Allogeneic Hematopoietic Stem Cell Transplantation: Etiology, Risk Factors and Outcome in a Single-Center Study. **2023**, 11, 742 ○
- 39 Frailty in Patients with Chronic Graft-versus-Host Disease. **2023**, ○
- 38 Kronisk transplantat-mot-vert-sykdom. **2023**, ○
- 37 Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia. 14, ○
- 36 Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). 11, ○
- 35 The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation. **2023**, 24, 5764 ○
- 34 Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy. 14, ○
- 33 Acute exacerbation of ocular graft-versus-host disease and anterior uveitis after COVID-19 vaccination. ○



- 32 The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation. **2023**, 29, 75-83 ○
- 31 Pruritus in cutaneous graft-versus-host disease: A systematic review. ○
- 30 Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT. 13, ○
- 29 Bronchiolitis obliterans syndrome following SARS-CoV-2 infection in an allogeneic hematopoietic stem cell recipient. **2023**, ○
- 28 Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study. ○
- 27 Psychological and physical function in allogeneic hematopoietic cell transplant survivors with chronic graft-versus-host disease. ○
- 26 Implication of machine learning for relapse prediction after allogeneic stem cell transplantation in adults with Ph-positive acute lymphoblastic leukemia. ○
- 25 Association Between Candidemia and Noninfectious Interstitial Pneumonia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. **2023**, 10, ○
- 24 The tear cytokine panel is a useful biomarker for early diagnosis and severity-evaluating of ocular chronic graft-versus-host disease. ○
- 23 Impact of Donor Age in Haploidentical-PTCy Versus MUD-PTCy HCT in AML patients. **2023**, ○
- 22 Comparison of efficacies of haploidentical transplantation and matched sibling donor transplantation in treating T-cell lymphoblastic lymphoma. ○
- 21 Hospital Dermatology: The Role of Dermatologists in Hospital Settings. **2023**, 2075-2103 ○
- 20 Influence of cyclosporine A trough level on acute graft versus host disease prophylaxis in pediatric allo- hematopoietic stem cell transplantation. ○
- 19 Transplantation Pathology. **2024**, 947-1038 ○
- 18 Allogeneic Transplantation for Immunodeficiency. **2023**, 1146-1160 ○
- 17 CD34 Stem Cell Boost in Pediatric Allogeneic Stem Cell Transplant Recipients: A Case Series and Review of Literature. ○
- 16 Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiotensin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor. **2023**, 24, 6960 ○
- 15 Pulmonary Manifestations of Hematological Malignancies. **2023**, 705-714 ○

- 14 Long-term health outcomes of allogeneic hematopoietic stem cell transplantation. **2023**, 13, 117-124. ○
- 13 Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stem cell transplantation for children and young adults with nonmalignant disorders. **2023**, 12, 117-124. ○
- 12 Post-hoc analysis of a clinical study on extracorporeal photopheresis in patients with chronic graft-versus-host disease in Japan. **2023**, 12, 117-124. ○
- 11 Grading of minor salivary gland immuno-histopathology post-allogeneic hematopoietic cell transplantation. **2023**, 9, e15517. ○
- 10 Graft-Versus-Host Disease (GvHD). **2023**, 241-267. ○
- 9 Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. **2023**, 18, e0284476. ○
- 8 Multi-parametric MRI in the diagnosis and scoring of gastrointestinal acute graft-versus-host disease. **2023**, 18, e0284476. ○
- 7 Metabolic syndrome as a late effect of childhood hematopoietic stem cell transplantation: A thorough statistical evaluation of putative risk factors. **2023**, 18, e0284476. ○
- 6 Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. **2023**, 18, e0284476. ○
- 5 Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced-Doses of Post-Transplant Cyclophosphamide: challenges and review of the literature.. **2023**, 18, e0284476. ○
- 4 Chronic graft-versus-recipient disease: Systematic review of joint and fascial involvement. **2023**, 18, e0284476. ○
- 3 Post-transplant cyclophosphamide as sole GVHD prophylaxis after matched reduced-intensity conditioning allotransplant. **2023**, 13, 117-124. ○
- 2 Impact of Iron Overload and Iron Chelation with Deferasirox on Outcomes of Patients with Severe Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation. **2023**, 62, 1355-1359. ○
- 1 Severe Erythroderma Due to Adult-onset Still's Disease-like Disease Related to Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. **2023**, 62, 1355-1359. ○